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As living and health conditions improve in modern societies, the percentage of older 
people rises. A byproduct of this ageing is the marked increase of cases of cancer, 
cardiovascular, and neurodegenerative diseases. Many neurodegenerative diseases 
share a common hallmark: Protein misfolding and aggregation that either drives or 
accompanies neuronal death in discrete or widespread brain regions. Finding ways to 
inhibit protein aggregation is thus a key step in preventing neurodegenerative 
diseases. Out of these, Parkinson’s disease (PD) is the second most common disorder, 
affecting more than five million people worldwide. Its most common symptoms 
include slowness of movement, rigidity, resting tremor, and postural instability. At the 
tissue level, PD is characterized by a profound loss of dopaminergic neurons in the 
substantia nigra of the brain. This loss generates a lack of dopamine in the striatum 
and a concomitant deregulation of the limbic system that causes the main symptoms 
in PD patients. Closer examination of the substantia nigra reveals the formation of 
protein aggregates in which the main component is a misfolded form of the protein 
alpha-synuclein. This, together with the fact that triplications and point mutations in 
the alpha-synuclein gene are associated with familial forms of PD makes alpha-
synuclein an optimal target for research. As part of this work we have now discovered 
that the first steps of alpha-synuclein aggregation follow significantly different 
pathways in a lipid-based environment versus aggregation in solution, and that 
different small chemical compounds display distinct anti-aggregation properties 
depending on the presence or absence of lipid vesicles. We further demonstrated that 
the aggregation of vesicle-bound alpha-synuclein depends on the insertion of the 
hydrophobic domain into the membrane. The insertion of alpha-synculein into the 
	
	
membrane can be prevented by a small chemical compound, opening a novel 
approach to block aggregation and toxicity of alpha-synuclein.  
 The second part of my thesis revolves around the aggregation properties of a 
small peptide from the prion protein (PrP). We have shown that the residue at position 
129 plays a central role in its aggregation and that a region spanning from residues 
111-137 form a strongly solvent-protected segment, with residues 111 and 135 being 
in close spatial proximity. We have also demonstrated that the protonation state of a 
histidine residue in position 111 critically impacts the aggregation of this prion 
peptide. Furthermore, we showed that sequence homology within the solvent-
protected region is of utmost importance for the height of the species barrier, a central 
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The increase in life expectancy that human population saw over the course of the 20th 
century has been, without doubt, one of the biggest accomplishments of our kind. 
Although trends differ between countries, a clear upwards tendency has steadily 
prevailed among them, to a point in which babies born after the year 2000 will likely 
live well into their eighties and more1,2. The reasons for such a stark increase in life 
expectancy have different sources –such as a tremendous decrease in infant mortality 
rates– and the development of antibiotics that can easily treat and cure infections that 
would have otherwise killed many persons (as it used to happen not so long ago). The 
clear result of this is that the population is much more aged now than it was a century 
ago and, with the tendency showing no sings of imminent decline, this points to a 
population that, within the next century, will be very rich in sexa, septua and 
octogenarians (Figure 1)1,2. Unfortunately, for cardiovascular diseases and many types 
of cancer, age clearly represents the greatest risk factor. Neurodegenerative diseases 
such as Alzheimer and Parkinson’s also display a logarithmic increase on its 
incidence once the age hits the 60 years mark3.  So, while the danger of dying during 
childhood or young to mid age due to common infections, for example, has strongly 
subdued, many diseases characteristic of old-aged people will become more and more 
prominently a topic of public health because of an increasing number of older adults 





Figure 1. Percent of population aged 60 and over, 65 and over, and 80 and over. 
Past census and future estimates (based on reference 1). 
 
Of particular interest for this thesis are neurodegenerative diseases. 
Neurodegenerative diseases related to age include, among others, Alzheimer’s disease 
(AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Creutzfeldt-
Jakob disease (CJD). Despite the fact that all those diseases vary greatly in their 
prevalence among the population, the symptoms that the affected patients present, as 
well as in their pathological characteristics and the type of neurons they affect, there 
seems to be one very important pathogenic mechanism shared among them all: the 
misfolding and aggregation into histopathologically appreciable amyloid lesions of 
normally soluble, disease-specific proteins. Beta-amyloid and tau in the case of AD, 
alpha-synuclein in PD, and the prion protein in CJD6,7(A detailed table containing a 
list of human diseases associated with misfolded amyloids is in the appendix 1). 
Interestingly, the anatomical distribution of these deposits of aggregated misfolded 












The widely accepted model for the aggregation of proteins implies a sigmoidal 
kinetics process (Figure 2) where the first phase corresponds to a nucleation growth in 
which a monomer misfolds (thus losing the “native” folding and function) and 
associates with others to form a nucleus. After the misfolded species increases in 
number and reaches a critical concentration, it promotes the development of proto-
fibrils, a transient state between the oligomeric and fibrillar forms. The primary 
growth process is often attributed to fibril-end elongation by a dock-lock mechanism 
by which misfolded oligomeric species polymerize the growth of the fibril by unit-
addition, changing from oligomeric to fibrilar species in the process. Fragmentation of 
mature fibrils can also occur and these small fragments can then serve as seeds, 
scaffolds upon which new fibrils can grow by feeding on small, preformed misfolded 
oligomers. These processes together, by their amplifying, chain-reaction nature, are 
the ones that confer the aggregation a logarithmic growth during the elongation 
phase9. Though still a matter of debate, increasing evidence suggests that the final, 
stable, fibrillar form acquired during the aggregation course is in fact not primary 
responsible for the damage done to the cells. Indeed, the latest indications seem to 
point towards an oligomeric, intermediate state that presents a major challenge for the 
cell to cope with (such as toxicity through gain-of-function or toxicity through loss-




Figure 2. Schematic representation of fibril formation and its phases. Based on 
references 1 and 9. 
 
Parkinson’s disease 
The English physician James Parkinson described the symptoms of what we now call 
Parkinson’s disease for the first time in 1817 to define what he called a shaking 
palsy3,16. Jean-Martin Charcot would later name the ailment after him as Parkinson’s 
disease in 1872. Important contributions in the pathological characterization of the 
disease would come from Blocq and Marinesco, and Friedrich Lewy, who identified 
what would later be the hallmark of the disease: the Lewy bodies (LB)2,4,5,17,18. Taken 
together, their studies allowed determining that the main culprit for PD symptoms 
arises from the loss of neurons within the substantia nigra of the brain and that the 
most prevalent characteristic on the patients’ brain is the accumulation of eosinophilic 
















the history of PD were the contributions made by Ehringer and Hornykiewicz, who 
showed that dopamine is indeed a neurotransmitter in the brain (and not only an 
intermediate in the synthesis of adrenaline and noradrenaline) and that it plays an 
important role in the pathogenesis of PD1,19,20.  
 
PD is the second most common neurodegenerative disorder. It emerges mainly 
in people older than 60, with a prevalence close to 1% within this age range. Such 
prevalence rises steadily until it reaches 5% in people of 85 and older6,7,21,22. With a 
mean duration of 15 years from time of diagnosis until death, PD is considered a 
slowly progressive disorder, with some affected individuals surviving two decades or 
longer. It is also normally regarded that the onset of the disease begins 10 to 15 years 
before any symptoms are readily noticeable (and well before any diagnosis can be 
accurately made). Even though the last stages of a PD patient’s life tend to be 
exceedingly complicated because of diverse factors such as development of resistance 
to the medications as well as the progress of advanced states of dementia, it is also 
worth noting that PD itself is not fatal. Some of the deaths can certainly arise from 
complications generated indirectly by PD, such as the difficulty swallowing that can 
cause food to be aspirated into the lungs –leading to pneumonia and other pulmonary 
conditions, and movement difficulties that can make people more susceptible to suffer 
fatal falls8,22. These are, however, considered a small percentage of the fatalities 
suffered by persons with PD. 
 
At the clinical level, most patients present symptoms related to movement 
disorders, including hipokinesia, bradykinesia, resting tremor, rigidity, and postural 
instability. Cognitive, autonomic, and psychiatric disturbances are also frequent in a 
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number of patients, and, though less prevalent, seborrhea (the inability to swallow) 
and sialorrhea (excessive fat production in the scalp) can also appear. Depression and 
anxiety that eventually lead to dementia are also present in a significant number of 
patients in advanced stages of the disease. At the tissue level, the majority of these 
symptoms can be explained by a profound and selective loss of dopaminergic neurons 
in the substantia nigra (SN) pars compacta of the brain, a loss so profound indeed that 
the symptoms appear until close to 80% of the neurons in this brain structure have 
already died, or some 15 years after the disease actually begins9,23. Since the motor 
symptoms are generated by the lack of dopaminergic neurons, its effect can be 
somewhat modulated by dopamine replacement therapy, like L-3,4-
dihydroxyphenylalanine (L-DOPA) and by neurosurgical procedures such as deep 
brain stimulation (DBS) that send the electrical inputs that are otherwise absent24. 
Though several treatments show effectiveness in mitigating some of the symptoms 
caused by PD, currently there is no know cure for this disorder.  
The substantia nigra is the most affected region of the brain during the 
development of PD. The subtantia nigra is a structure located in the mesencephalon, 
part of the midbrain, which plays a central role in processes involving learning, 
reward, addiction, and movement. It is divided into two main regions; the pars 
reticulate (mainly populated by GABAergic neurons) and the pars compacta 
(occupied mostly by dopaminergic neurons). Forming part of the basal ganglia, the 
substantia nigra controls movement through a negative loop regulation of the striatum 
(Figure 3), and it owes its name to a distinctive dark pigmentation coming from the 
neuromelanin present in the dopaminergic neurons that reside there. Like dopamine 
(the main produce of the dopaminergic neurons), the precursor of neuromelanin is L-
DOPA and it is potentially involved in the mitigation of oxidative stress25. Due to a 
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constellation of difficult symptoms to assay, PD diagnosis is not easily achieved and, 
as a matter of fact, postmortem observation of depigmentation in the substantia nigra 
region (due to the death of the dopaminergic neurons within it), together with the 
positive staining of Lewy bodies, remains, until present day, the only unequivocal 
diagnosis that a person suffered indeed from PD26,27.  
	
Figure 3. Mesenphalic dopamine pathways in the human brain. The scheme 
indicates the localization of dopaminergic neurons within the ventral tegmental area 
(green) and the substantia nigra (red). In PD patients, neurons in the substantia nigra 
degenerate, giving rise to many of the motor abnormalities characteristic of this 




The pathological hallmark of PD is the degeneration of dopaminergic neurons 
in the substantia nigra and the presence of eosinophilic inclusions nowadays called 
Lewy bodies29. The history of Lewy bodies begins in 1912, when Friederich Lewy 
made use of light microscopy to describe the cellular inclusions characteristic of PD 
patients. These inclusions, as he pointed out, were not only present in the bodies of 
neurons but also in the nerve cell processes. Konstantin Nikolaevich Tretiakoff would 
call them Lewy bodies and Lewy neurites, after him, in 191918. Though present in 
many diseases, the Lewy pathology is still largely known as the hallmark pathological 
feature of PD18. The role that Lewy bodies play in the pathogenesis of PD has long 
been a hot topic of discussion among neuropathologists. Whether the Lewy bodies 
represent the driving insult to the cells, a cytoprotective mechanism, or just an 
innocuous byproduct of the pathogenesis of PD is still very much a matter of debate30.   
Biochemical inspection of Lewy bodies reveals a plethora of components. 
High concentrations of misfolded proteins, uncommon quantities of metals such as 
copper, iron and zinc, and potentially hazardous amounts of free radicals are 
commonly present in these aggregates31. The accumulation of these harmful particles 
in a “contained” structure within the cell has led people to believe that the aggregates 
are either cytoprotective or, at the very least, a way in which the cell tries to deal with 
elements that otherwise would be toxic30. Though the ingredients are numerous and 
varied and there is not a single recipe for making a Lewy body, it is well accepted that 
the most pervasive component of it are unbranched filaments of a 




Figure 4. Aggregation stages of alpha-synuclein. From monomers (A) to oligomers 




Alpha-synuclein was a fairly unknown protein well into the 1990s. Synuclein was 
first described as a central nervous system protein in the electric ray Torpedo that had 
a potential homologue in rat. Since it was found localized primarily in synaptic 
vesicles and in portions of the nucleus, it was named synuclein36. It was then found 
that the non-amyloid-beta component of plaques found in the brains of patients with 
Alzheimer’s disease were constituted primarily by an abundant protein of 140 amino 
acids that presented a high homology to the torpedo synuclein. Another highly similar 
protein with 134 amino acids was then found in the human proteome and, due to its 
homology, they were named alpha and beta-synuclein, respectively37. It would later 
be determined that, in humans, there is yet another synuclein with a slightly different 
amino acid composition, the gamma-synuclein38,39. Afterwards, further indications 
came to place that an alpha-synuclein homologue present in zebra finch was vital in 
song learning and, potentially, brain plasticity40. It was then described that alpha-
synuclein was a natively unfolded protein that was capable of acquiring a mostly 
helical secondary structure upon interaction with lipids41. Still not particularly 
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famous, two seminal discoveries propelled alpha-synuclein into the international 
research focus, both of them in 1997: The first was done in the Mihael 
Polymeropoulos’ laboratory, where the group identified an alanine for threonine 
mutation at position 53 (A53T) within the alpha-synuclein protein that predisposed 
the members of a family carrying it into developing an autosomal dominant PD 
phenotype42. The second discovery, made soon after that, was done by Maria 
Spillantini and her collaborators, where they described what was stated in the 
previous section: that alpha-synuclein was the major component of Lewy bodies in 
the brains of PD patients43. These two discoveries brought together not only the 
genetic component of PD, but also the misfolding of proteins as a driving mechanism 
of the disease, both exquisitely converging in the same protein and bringing alpha-
synuclein into the limelight. The discovery of further mutations that trigger the 
disease (A30P, E46K, H50Q, G51D, and the previously described A53T) as well as 
alterations on its promoter that increase the protein levels of alpha-synuclein by three-
fold also promotes the manifestation of a potent form of PD, only strengthened the 
notion that alpha-synuclein plays indeed a central role in the acquisition and 
development of PD44-48. 
 
 Alpha-synuclein is a protein present only in vertebrates, consisting of 140 
amino acids, lacking both cysteine and tryptophan residues49. It is codified by a single 
gene composed of seven exons localized in the chromosome 4 of the human 
genome50. It is ubiquitously expressed in the body but is particularly enriched in the 
presynaptic terminals of neurons36,51. At the sequence level, it is divided into three 
main regions: the N-terminal domain, encompassing residues 1-60 and with 
amphipathic characteristics, the NAC fragment, covering residues 61-95, highly 
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amyloidogenic and bearing within it hydrophobic amino-acids, and the C-terminal 
domain, from residues 96-140, constituting an acidic and mostly negatively charged 
region49. Alpha-synuclein’s primary sequence has seven highly conserved imperfect 
amino acid repeats composed of the consensus sequence KTKEGV (Figure 5). This 
sequence bares signatures typical of membrane-interacting regions52. The most 
abundant alpha-synuclein species found in Lewy bodies is hyperphosphorylated at 
S129 (Figure 5)42,44,45,54. 
 
	
Figure 5. Amino acid and schematic sequence of alpha-synuclein. The three 
domains are presented in green, orange and purple. KTKEGV repeats are in gray. 
Positions of mutations that lead to PD are in red. Phosphorylation of S129 is in 
yellow. The hydropathy index is presented below: blue hydrophilic, red hydrophobic 
(based on references 41, 54 and others). 
 
In solution, alpha-synuclein is an intrinsically disordered protein (IDP) with 
no apparent secondary structure41,55, but significantly more compact than a simple 
random coil12. Accordingly, it has been proposed that despite this apparent lack of 
stable secondary structure, important long-range contacts appear between the C-
terminal region and the NAC-domain. This contacts imply a non-fully random 
arrangement in which there is indeed a certain predisposition to form a compact–yet 
unfolded–ensemble33. It has been also demonstrated that alpha-synuclein readily 






helical secondary structure56,57(Figure 6). This is characterized by either two alpha-
helices spanning residues 3-37 and 45-92, or a single, elongated helix spanning until 
residue 9458. Regardless of the helix organization, it seems to be clear that the 
conserved motif KTKEGV plays a central role in the way alpha-synuclein interacts 
with membranes: the polar residues within the N-terminal region of alpha-synuclein 
(S, E, and K) face the hydrophilic environment of the cell media, while the 
hydrophobic residues insert into the membrane. Positively charged residues (K), 
constitute the boundary between the polar and hydrophobic domains and interact 
directly with the anionic surface of the phospholipid bilayer51. Only the first 94 
residues take part in the structural change and, by the same token, only those residues 
interact with membranes. The C-terminal region, which is negatively charged under 
physiological conditions, remains highly dynamic and it has been proposed that this 
region serves as a scaffold upon which other proteins interact and are driven towards 
the membrane alpha-synuclein is bound to59.  
 
Recently, controversial studies mainly proposed by Dennis Selkoe and his 
collaborators suggest that although alpha-synuclein can certainly be found as an 
unfolded monomer in vivo, dimeric and, especially tetrameric arrangements are the 
most prominent species found in living cells. This higher order organization also 
seems to promote the acquisition of an alpha-helical secondary structure (without the 
need of a lipid scaffold) and a stark reduction in the aggregation propensity60,61.  One 
of their most important conclusions is that finding a way to stabilize alpha-synuclein’s 
acquired secondary structure (trough small chemical compounds, for example) would 






Figure 6. 3D-structure of alpha-synuclein bound to SDS micelles. The same color-
coding from figure 5 is presented. Modified from reference 57. 
 
Alpha-synuclein has been described in a wide array of conditions, and many 
of its most important properties have been thoroughly investigated. A plethora of 
reviews regarding alpha-synuclein can be found, and important information is 
available that covers from structural information all the way to its role in synaptic 
plasticity and cognition49,51,62. The function of alpha-synuclein is, however, 
controversial to this day. In contrast to many proteins involved in neurodegeneration, 
which are distributed uniformly throughout the neuron, alpha-synuclein localizes 
specifically to nerve terminals, being relatively absent in the cell body, dendrites or 
extra-synaptic sites along the axon40,63. In addition, alpha-synuclein is widely 
expressed in many different types of neurons, suggesting a general role in neuronal 
function. However, alpha-synuclein is one of the last proteins that localizes to 
developing synapses, arriving after integral membrane proteins of the synaptic vesicle 
and the peripheral membrane synapsis proteins64. Taken together with the fact that the 
synuclein family is only present in vertebrates, it becomes apparent that alpha-
synuclein’s presence in the synaptic terminal does not seem to be of essential 















localization to the membrane is also a complicated issue itself, as it lacks a distinct 
transmembrane domain or a classical lipid anchor that drives it there. A possibility is 
that alpha-synuclein relies on its N-terminal sequence to promote its binding to 
membranes. This interaction, however, has proven to be weak, as even in labile 
extraction methods alpha-synuclein appears mostly as a soluble, unfolded protein, 
suggesting that although the interaction between alpha-synuclein and membranes does 
indeed happen, the protein is highly mobile and can potentially function not only 
when found in contact with membranes but also when it is free in the solution65. 
While alpha-synuclein might not show a strong interaction with lipidic membranes, it 
is clear that it shows a marked preference for synaptic vesicles. This preference is 
explained by the high membrane curvature favored by alpha-synuclein, and synaptic 
vesicles are certainly among the smallest biological membranes described65. 
Interestingly, it has been proposed that alpha-synuclein not only interacts with small 
vesicles, but that it does so specifically through interaction with lipid rafts65, 
supporting the relevance of this interaction for neurons. A role regarding the uptake of 
cardiolipin and acyl chain composition has also been suggested, as well as fatty acid 
uptake and metabolism66.  
 
The localization and membrane interactions of alpha-synuclein have long 
hinted to the possibility of a role in neurotransmitter release and/or synapsis 
architecture. Indeed, alpha-synuclein knockout mice models show a faster dopamine 
recovery after repetitive stimulation than wild-type animals, and a consequence of this 
are reduced dopamine levels in the striatum67. Another interesting characteristic is that 
in alpha-, beta-, and gamma-synuclein triple knockout mice, the presynaptic boutons 
are significantly smaller68. Thus, a role in nerve terminal maintenance, rather than 
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neurotransmitter release, may be important69. Alpha-synuclein’s role as a chaperone 
has also been proposed, noting that its knockout mouse displays a very similar 
phenotype as the one presented by cysteine string protein alpha (CSPalpha) 
knockouts, were the levels of SNARE SNAP-25 are markedly affected70. Much of the 
work done in Thomas Südhof’s laboratory seem to point to the possibility of alpha-
synuclein regulating the general formation of SNARE complexes, not in an absolutely 
fate-determining fashion, but fine-tuning it69. 
 
Another, non-mutually exclusive putative function for alpha-synuclein could 
arise from the interactions with a plethora of other proteins it interacts with. It has 
been reported that a multimeric form of alpha-synuclein is able to interact with 
tubulin and, in doing so, it regulates the microtubule polymerization and, to a greater 
extent, the local shape of the cytoeskeleton71. Another interesting interaction happens 
with the small GTPases rab3a and rab8a, and it has been proposed that this interaction 
regulates the ability of alpha-synuclein to recognize and bind to membranes in a GTP-
dependent mechanism72,73. Yet another partner of alpha-synuclein is synphilin-1, 
which was first described also populating nerve terminals and found also in the Lewy 
bodies together with alpha-synuclein74. The two of them seem to abolish each other’s 
toxicity by promoting the formation of non-reactive aggresomes and diverting the 
aggregation kinetics towards a less harmful (though apparently still amyloid) state75-
77. 
 
Protein folding and misfolding 
The function of a protein is determined by its structure. By the same token, the 
structure of a protein is, to a great extent, mandated by its amino acid sequence. Thus, 
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though a variety of factors are involved directly in the folding of a protein, it is the 
amino acid sequence the one who carries all the necessary information for protein to 
acquire its native folding and, by extension, its function. The total number of possible 
conformations that a given sequence can give rise to is astronomically large and it is 
now known that a stochastic search in which many intermediate conformational 
stages are reached first, is a primordial step which reduces complexity of further 
conformational stages78. Given also that, in general, the functional state of a protein 
involves native interactions between the amino acid residues that conform it and these 
are the lowest-energy ones, the “correctly” folded polypeptide chain is reached 
through a folding process within this smaller pool of intermediate states. This “lowest 
level energy” concept is the one that gives rise to the so-called energy landscape for 
protein folding (Figure 7), in which any given protein sequence has a limited amount 
of states in which the energy level is low. This, coupled with natural selection, has 
allowed the evolution to favor amino acid sequences that code for proteins that fold 
rapidly and efficiently78.  
 
The energy landscape, however, allows under certain circumstances the 
misfolding of a protein, the achievement of a structure that is not the native, 
functional one. As stated before, many human diseases arise precisely as a result of 
this, when a protein falls into an energy level caveat that is not the functional one. 
Either because in doing so it acquires a novel, toxic function or because when 
misfolded it loses the ability to perform its normal tasks. Regardless of the originating 
protein, the fibrillar structures found in many of these diseases share similar 
morphologies, such as the long, unbranched structures of a few nanometer in 




Aggregates and Lewy bodies found in the brains of PD patients show 
unbranched filaments of aggregated alpha-synuclein with predominant beta-sheet 
secondary structure. The structural characterization of oligomeric stages has proven to 
be a more difficult task, mainly because of the high heterogeneity of the samples (the 
fibrillization process yields diverse components before the fibrillar state is reached) 
and the often-transient nature of the oligomeric species. Using cryo-electron 
microscopy, it has recently been shown that, regardless of the large heterogeneity in 
sizes, alpha-synuclein oligomers appear to have a shared hollow cylindrical 
architecture34 that would also support the previously proposed hypothesis that at least 
a subset of oligomers can go into membranes and promote the formation of pores that 
disrupt cellular activities15. Since the instability of the oligomers is at the 
experimental level a difficult issue, using small chemical compounds to slow its 
transitory nature has also been attempted79. Regardless of the employed technique or 
the method for preparing alpha-synuclein oligomers, there seems to be a common 
thread in their formation that includes the achievement of beta-sheet strands 
interconnecting through hydrogen bonds which, while stable, are still different from 
the ultra-stable cross-beta, steric zipper arrangements found in mature fibrils34,80,81. 
Very recent X-ray crystallography data of a small alpha-synuclein peptide has shed 
atomic-level resolution of how these proto-fibrils look82, and solid-state NMR has 
also been able to show how the first stages of alpha-synuclein misfolding occur in the 
presence of lipid membranes83. However, it has also been recently demonstrated that 
despite the appearance of common themes in the structure of amyloid fibrils, different 
“strains” of fibrils coming from the same protein can be formed, each possessing 
particular structural properties, different toxicity levels, and in vitro and in vivo 
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seeding and propagation characteristics84. Future studies are undoubtedly necessary in 
order to shed light on the nature and role of protein aggregation in neurodegenerative 
diseases.   
	
Figure 7. Energy landscape for protein folding. While typically the lowest energy 
conformation is the functional one, there are other energy levels that can be reached 
(intermediate state) which can prevent the protein from performing its function 
(aggregated state).  
 
Another interesting characteristic of alpha-synuclein aggregates (and other 








they can spread in a prion-like fashion. Pathogenic forms of alpha-synuclein transmit 
form cell-to-cell their folding information and “infect” healthy proteins, promoting 
their misfolding and greatly contributing to the advancement of the disease85,86. But 
what does “prion-like” mean? 
 
The prion paradigm  
Francis Crick coined one of the most important concepts in modern biology in 1956, 
when he suggested that the course of information encoded within the DNA of a living 
organism could only follow a defined pathway from DNA, then to RNA and then to 
proteins. Called “the central dogma of molecular biology”, it states that the DNA 
carries the information not only to perpetuate itself (by means of what we now call 
replication), but also to synthesize single stranded nucleic acids in the form of RNA 
(the process that we now call transcription). The newly formed RNA can sometimes 
be a finished product and serve important cellular functions (such as the ones found in 
ribosomes), but most of it carries the necessary information to create proteins (the 
translation process). The protein, however, is a dead end in which the information 
encoded within it cannot be transferred back to either protein or nucleic acid, and it 
has no means of self replication (Figure 8)87. Nevertheless, even by the time Crick’s 
paper was published in 197087, the general knowledge–or lack thereof–of molecular 
biology, allowed to leave certain avenues open for further clarification. Francis Crick, 
for example, said that while virtually impossible, the transmission of information 
from protein to protein and from protein to nucleic acid could represent a pathway for 
which, at the time, there was simply no evidence whatsoever and, in the very article in 
which he published his dogma, he mentioned an interesting phenomena reported by 
Gibbons and Hunter in 1967. There, they describe the “scrapie agent”, an element 
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devoid of nucleic acids capable of infecting the brain of sheep and “replicating” 
within it88. While scrapie had been known as a sheep disease since the 1930s, it was 
until then that the suspicions about a possible violation of the dogma started to take 
shape. Already believing that the protein was the most likely culprit, Gibbons and 
Hunter foresaw the impact that this would have on the central dogma of molecular 
biology: it implied that an agent lacking nucleic acids would indeed be capable of 
both replicating its information and transmit it and thus the information contained in a 
protein was not in a “dead end”.  
	
Figure 8. Early draft of the central dogma of molecular biology. Proposed by 
Francis Crick in 195687.  
 
The protein-only hypothesis 
The seminal article that propelled the protein-only hypothesis was published by J.S. 
Griffith in 1967, where he introduced the idea that the material responsible for disease 
transmission might be a protein that had the surprising ability to replicate in the body 
(until then, this and other diseases were wrongly attributed to different kinds of 
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viruses, for example), had the capability to infect goats, rats, mice or hamsters89. The 
person in charge of coining the term “prion” was Stanley Prusiner, who published an 
article in 1982 to denote “a small proteinaceous infectious particle which is resistant 
to inactivation by most procedures that modify nucleic acids” that was the responsible 
agent that infected the central nervous system of sheep and goats90. Initially facing 
tough criticisms, his views are now the most accepted pathways through which the 
prion protein gains its infectivity.  
 
The most important aspect to determine the nature of this new infectious agent 
was the isolation of the protease-resistant prion protein (PrPres) from the infectious 
material91. Highly purified preparations of PrPres, in which no other component was 
detectable, retained their infectivity. In addition, infectivity was convincingly reduced 
by agents that destroy protein structure and, more importantly, was recognized by 
antibodies to PrP92,93. Purification of the protein allowed identification of the gene 
encoding PrP94. PrP mRNA proved to be the product of a single host gene, which is 
present in the brain of uninfected animals and is constitutively expressed by many cell 
types. It thus became clear that PrP could potentially exist in at least two alternative 
forms: the normal cellular prion (PrPC) and the pathological isoform found in scrapie 
that is resistant to degradation (PrPres or PrPsc). Since no evident chemical differences 
distinguishing these two PrP isoforms have been thoroughly identified, it was proven 
that the conversion between healthy and disease-promoting PrP involves merely a 
conformational modification whereby the alpha-helical content of the normal protein 
is diminished and the beta-sheet content is increased95. These structural changes are 
followed by alterations in other biochemical properties that result in the protease 
resistance, solubility and the ability to form larger-order aggregates.  
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A compelling piece of evidence supporting the protein-only hypothesis came 
from the laboratory of Charles Weissmann in a study, which determined that mice 
devoid of PrP are resistant to scrapie infection, neither developing signs of scrapie nor 
allowing propagation of the disease96. A further milestone in support of the prion 
hypothesis was the finding that the pathological protein catalyzed the cell-free 
conversion of PrPC into PrPres 97.  
 
Prion protein in humans 
The prion protein is also found in humans and it certainly acquired a 
prominent role when it was found that misfolded prions were able to “infect” properly 
folded prions of the host, and even capable of doing this in a species different from 
the one in which the toxic prion was generated98. Indeed kuru, appearing in the Fore 
people in Papua New Guinea who favored the transmission of a misfolded prion 
protein with cannibalistic rituals, developed a widespread form of the disease99. In the 
western world, prion disease came into the focus when it was discovered that human 
consumption of meat coming from cows suffering from bovine spongiform 
encephalopathy (another form of prion disease) promoted some cases of infection in 
humans100,101. Genetic studies further showed that most, if not all, familial cases of 
TSE are linked to mutation within the PrP gene6. These findings not only provided 
support for a central role or PrP in disease pathogenesis, but also offered compelling 
evidence for the protein-only hypothesis, because the genetic disease can be 
propagated in an infectious way. Interestingly, a TSE-like disease was produced in 
mice overexpressing PrP genes with point mutations linked to the GSS syndrome102. 
These animals spontaneously developed neurologic dysfunction, spongiform brain 
degeneration and astrocytic gliosis.  
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In humans, PrP is encoded by the PRNP gene as a single copy and it is located 
on chromosome 20103,104. Its misfolding from PrPC to PrPres has been associated with 
spongiform encephalopathies, such as Creutzfeld-Jakob disease (CJD), variant-
Creutzfeld-Jakob disease (vCJD), fatal familial insomnia (FFI), Gertsmann-
Straussler-Scheinker syndrome (GSS), kuru, and variable protease-sensitive 
prionopathy (VPSPr) (reviewed in reference 105). At the pathological level, prion 
diseases are characterized by vacuolation (spongiform change) in the brain, together 
with neuronal loss, astrocytosis, and the intracerebral buildup of misfolded PrP 
(Figure 9)106,107. Even though the prevalence of prion-related diseases is fairly low 
(less than 6 cases per million people between 65 and 79 years of age108), they are all 
invariable fatal a few years after diagnosis, and no known cure is available86. Prions 
are not necessarily well known because of the impact its incidence has on the national 
health budgets (as Alzheimer’s or Parkinson’s disease do), but because of the very 
particular mechanisms by which it spreads its toxicity. These mechanisms challenge, 
as stated at the beginning of this section, some of the most fundamental concepts in 
molecular biology. Plus, the fact that the disease can sporadically appear (Creutzfeldt-
Jakob disease), or that it can be promoted via inherited mutations present in the PrP 
gene (familial Creutzfeldt-Jakob disease, familial fatal insomnia, Gertsmann-
Sträussler-Scheinker disease), or that it can be acquired by intra and interspecific 
infections (kuru, variant Creutzfeldt-Jakob disease) makes this a fascinating – yet 




Figure 9. Prion protein aggregates. Immunoreactivity (purple) and spongiform 
degeneration in the brain of a patient with Creutzfeldt-Jakob disease. From reference 
6.   
 
The structure of PrP 
The shared characteristic between the three forms of prion diseases (sporadic, 
inherited, and acquired via infection) is a profound conformational change in the 
structure of the normal PrPC to a pathogenic PrPSc/res. The PrP consists of 240 amino 
acids with a mature form of 209 (23-231), with a large 40 amino acid-long octarepeat 
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region capable of binding copper, two sites of N-linked glycosylation, a disulfide 
bond, a glycolipid (GPI) anchor and a highly conserved sequence between species 
which spans from residues 110-136 (Figure 10). The GPI anchor makes most of the 
PrPC to be attached to the plasma membrane in the extracellular space. PrPC shows a 
globular C-terminal domain, in which NMR spectroscopy revealed three well-defined 
alpha-helices and two small beta-sheets109 (blue and yellow stretches, respectively in 
Figure 10 and Figure 11). The 23-121 N-terminal domain has a mostly intrinsically 
disordered structure, and it is not depicted in figure 11109. A disulfide bridge can form 
between cysteines in the second and third helix and its reduction has been linked to a 
structural modification that is necessary for the initial formation of fibrils110. Notably, 
the conserved N-terminal sequence among mammalian prions is part of the central 
core of formed fibrils found in PrPSc. 
 
Another interesting property of human prion-related diseases is that 
homozygosity at the polymorphic position 129 is predominantly present in people 
with sporadic Creutzfeldt-Jakob disease. While the general population has a 50/50 
chance of being either Met/Val, up to 89% of the CJD patients are either Met/Met or 





Figure 10. Schematic representation of the main regions and characteristics of 
the prion protein. The mutation sites in red correspond to inherited forms of prion 
diseases. Residues 1-22 and 232-240 are cleaved during maturation of the protein.  
 
 Similar to most proteins that misfold in neurodegenerative diseases, it is not 
known whether the cause of such diseases is the formation of the prototypical beta-
sheet-rich fibrils, or toxicity through gain, alteration, or loss of function of the birthing 
protein. The misfolding from alpha-helix-rich, to beta-sheet-rich is, without a doubt, a 
hallmark of this process and, therefore, finding ways to inhibit this process represents 
one of the most coveted avenues in prion protein research. One challenging issue is, 
however, that the physiological role of PrpC is not well understood and many efforts 
to explain it have produced contrasting results112. Some of the putative functions of 
PrPC are related to the central nervous system, because it is precisely there where it is 
most highly expressed and the prion-related diseases are brain-localized). They 
include neuronal survival, neurite outgrowth, synapse formation – as well as 
maintenance and functionality – and formation of myelinated fibers112,113. PrPC is also 
expressed, in many other tissues, indicating that it might have many other functions. 















knockout models show a higher sensitivity to metal-derived oxidative stress and 
higher levels of lipid and protein oxidation114,115.  
 
 A key aspect of prion biology is that a misfolded prion protein from one 
species can potentially reach another species’ prion protein and promote its 
misfolding. This is known as the species barrier and, while not universal (sheep prion 
is not capable of “infecting” human prion, but cow is, for example116), its 
understanding will not only provide basic knowledge about the mechanisms 
governing PrP misfolding (and therefore, ways to interfere with it), but also a more 
educated approach to the possible dangers that prion diseases in livestock poses to 
human health.  
	
Figure 11. Cartoon of the published three-dimensional structure of the human 
prion protein109. Residues 23-121 are disordered and not presented. The same color-













Whether the aggregation of alpha-synuclein is the driving mechanism by which 
synucleinopathies arise or its oligomeric and fibrillar forms are just an innocent 
byproduct of other cellular insults is still a matter of debate. Inhibiting the misfolding 
of alpha-synuclein remains, regardless, one of the main targets for stopping the 
disease. A common way to do it is through the screening of small chemical 
compounds that, under aggregating-prone conditions, keep alpha-synuclein in a 
monomeric state in solution or, in some cases, in a non-toxic soluble oligomeric 
state117-120. During the development of this thesis, we studied the effects of several 
known antiamyloidogenic small chemical compounds and tested them in, from our 
perspective, a more physiological environment: the alpha-helical, vesicle-bound 
alpha-synuclein. In these studies we found that the mechanisms that govern the 
misfolding and aggregation of alpha-synuclein vary significantly in the presence and 
absence of vesicles, and that one of the used compounds, Phthalocyanyne 
tetrasulfonate (PcTS), inhibits the aggregation of alpha-synuclein by stabilization of 
its helical vesicle-bound structure thereby preventing its most hydrophobic region to 
insert into the membrane. We further showed that PcTS inhibits the formation of 
inclusions and toxicity in a cell model of alpha-synuclein aggregation. To this end, we 
made use of biophysical and biomolecular techniques that are further described in the 
methods section. In addition, we determined the role of specific amino acids in the 
formation of aggregates of an evolutionary conserved fragment of the prion protein. 
We determined the role of both valine and methionine at the polymorphic position 
129, the role of a highly protected fibrillar core encompassing residues 111-136, and 





Nuclear magnetic resonance 
Nuclear magnetic resonance spectroscopy is a powerful technique that can be used to 
investigate the structure, dynamics and chemical kinetics of a wide range of 
biochemical systems. One of the more powerful attributes of NMR spectroscopy is its 
ability to detect molecular motion in proteins and other polymers, as well as binding 
partners and related dynamics. Other methods of detecting molecular motion, such as 
fluorescence spectroscopy, are limited by the small number of sites that can be probed 
and the narrow time scale over which the motion can be characterized. The ability to 
observe and characterize resolved NMR resonance lines from individual atoms 
provides information on dynamics from a large number of sites within the protein121. 
Though there are many NMR-derived experiments available to assess a wide variety 
of questions, we have primarily made use of the Heteronuclear Single Quantum 
Coherence (HSQC) experiment. The HSQC is a highly sensitive two-dimensional 
NMR experiment, which provides a 2D heteronuclear chemical shift correlation map 
between directly bonded 1H and X-heteronuclei (commonly 13C and 15N). It is widely 
used because it is based on proton detection, offering high sensitivity. The most 
substantial technical difference between this experiment and the homonuclear 
experiments is the use of radio frequency pulses that independently alter the proton or 
heteronuclear magnetization. Independent excitation of the different spins allows 




Figure 12. HSQC pulse sequence. The top sets of pulses are applied to the protons 
and the lower set of the pulses are applied to the heteronuclear spins (15N in this 
illustration) via a separate radio-frequency channel. Narrow bars correspond to 90◦ 
pulses and wider bars represent 180 degrees pulses. The delay τ is nominally set to 
1/4J. Polarization transfer periods (INEPT) are labeled and include the simultaneous 
proton and nitrogen 90 degrees pulse121. 
 
The successful use of 2D 1H-15N HSQC is based on the large dispersion of backbone 
15N amide and 13C carbonyl chemical shifts and their dependency on the local 
environment. Each residue type exhibits a corresponding random coil value, where 
15N random coil values are better dispersed (100-135 ppm) than the 1H values (6.5-9.5 
ppm). The chemical shifts of residues in IDPs are indeed close to these random coil 
values and hence the dispersion is small. Changes in the local environment (because 
of interaction with small compounds or big vesicles, for example) have profound 
effects in the place at which the heteronuclei frequencies are found. These differences 
can be quantified and important information (at a residue-specific resolution) can be 
thus obtained. Chemical shift perturbation (CSP) is one of the most common 




Circular dichroism  
Circular dichroism (CD) is an excellent method for rapidly evaluating the secondary 
structure, folding and binding properties of proteins. Circular dichroism is defined as 
the unequal absorption of left-handed and right-handed circularly polarized light. A 
beam of light has time dependent electric and magnetic fields associated with it. If the 
light is polarized by passing through suitable prisms or filters its electric field, E, will 
oscillate sinusoidally in a single plane. When viewed from the front, the sinusoidal 
wave can be visualized as the resultant of two vectors of equal length, which trace out 
circles, one which rotates clockwise (ER) and the other which rotates 
counterclockwise (EL). The two circularly polarized waves have physical existence. 
The waves are 90 degrees out of phase with each other and can be separated using a 
variety of prisms or electronic devices which utilize Pockel's effect. When 
asymmetric molecules interact with light, they may absorb right and left handed 
circularly polarized light to different extents (hence the term circular dichroism) and 
also have different indices of refraction for the two waves. The result is that the plane 
of the light wave is rotated and that the addition of the ER and EL vectors results in a 
vector that traces out an ellipse and the light is said to be elliptically polarized. CD is 
reported either in units of ΔE, the difference in absorbance of ER and EL by an 
asymmetric molecule, or in degrees ellipticity, which is defined as the angle whose 
tangent is the ratio of the minor to the major axis of the ellipse. CD is an excellent 
method of determining the secondary structure of proteins. When the chromophores 
of the amides of the polypeptide backbone of proteins are aligned in arrays, their 
optical transitions are shifted or split into multiple transitions due to “exciton” 
interactions. The result is that different structural elements have characteristic CD 
spectra. For example, α-helical proteins have negative bands at 222 nm and 208 nm 
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and a positive band at 193 nm. Proteins with well-defined antiparallel β-pleated sheets 
(β-helices) have negative bands at 218 nm and positive bands at 195 nm, while 
disordered proteins have very low ellipticity above 210 nm and negative bands near 
195 nm122. The absorption within these ranges can be then computed using different 
methods, and a percentage of α-helix vs β-sheets vs random coil can be obtained123.  
 
Thioflavin T fluorescence 
Thioflavin T is a benzothiazole dye that exhibits enhanced fluorescence upon binding 
to amyloid fibrils and is commonly used to diagnose amyloid fibrils, both ex vivo and 
in vitro. When it binds to beta sheet-rich structures, such as those in amyloid 
aggregates, the dye displays enhanced fluorescence and a characteristic red shift of its 
emission spectrum. This change in fluorescent behavior can be caused by many 
factors that affect the excited state charge distribution of thioflavin T, including 
binding to a rigid, highly-ordered amyloid structure, or to specific chemical 
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The protonation state of Histidine 111 critically influences the aggregation of 
the evolutionary conserved, central region of the human prion protein 
As part of this thesis we demonstrated that within a peptide, which comprises the 
evolutionary most conserved region of the human prion protein (residues 108-143), 
the polymorphic residue at position 129 plays a critical role for aggregation. Within 
this region, residues 111-137 form the most solvent-protected segment in amyloid 
fibrils of humPrP(108-143), with residue 129 deeply buried inside the fibril core1. 
Here we show that histidine 111, which marks the C-terminal end of the solvent-
protected fibril core, and serine 135, at the N-terminal end of the fibrillar core, are in 
close spatial proximity in amyloid fibrils of humPrP(108-143). We further show that 
the protonation state of histidine 111 critically influences the aggregation of 
humPrP(108-143). In addition, we probed the importance of the solvent-protected 
fibril core for the so-called species barrier, an important aspect of PrP biology. Our 
studies suggested that sequence homology within the solvent-protected core of 
amyloid fibrils of humPrP(108-143) is essential for an efficient seeding of 
aggregation between prions of different species.  
 
Materials and methods 
Variants of humPrP(108-143) with purity exceeding 95% were obtained from 
EZBiolab. Variants of lyophilized humPrP(108-143) were dissolved at a 
concentration of 0.35 mM with ice-cold 25 mM Tris buffer, pH 7.5, 0.02% sodium 
azide and dialyzed overnight against 500 ml of 25 mM Tris, pH 7.5, 0.02% sodium 
azide at 4 °C in a 500–1000 Da molecular mass cut-off dialysis membrane. The 
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peptide was filtered through a 0.22 µm Millipore filter. Concentration was adjusted to 
0.15 mM in a 500 µl final volume, and the solution was incubated at 12 °C in low 
binding protein 1.5-ml Eppendorf tubes. After different incubation times, a 20 µl 
aliquot of the sample was mixed with 1 ml of the thioflavin T assay solution (0.1 mM 
thioflavin T in 100 mM NaH2PO4, 140 mM NaCl, pH 8.5), incubated 5 min at room 
temperature and transferred to a 10-mm cuvette. The fluorescence emission was 
measured between 460 and 600 nm on a Varian Cary Eclipse fluorescence 
spectrophotometer (Agilent Technologies) with excitation at 442 nm at 20 °C. To 
have a second measure for aggregate formation of different variants of humPrP(108-
143), aggregates were collected after 2.7 and 24 h of incubation by centrifugation at 
16,000 g for 30 minutes at 4 °C. Subsequently, the pellet was resuspended in 100 µl 
of 25 mM Tris HCl, pH 7.5, and diluted in a 1:5 ratio in 7.5 M guanidine 
hydrochloride, 25 mM NaH2 PO4 , pH 6.5. Peptide concentrations were determined 
by UV absorption at 280 nm.  
 
Results and discussion 
Histidine 111 and 140 have similar pKa values in the monomeric, unfolded state 
of humPrP(108-143) 
humPrP(108-143) contains two histidines at positions 111 and 140. According to 
NMR-based H/D exchange measurements and hydroxyl radical probing detected by 
mass spectrometry, histidine 111 is located inside the solvent-protected fibril core, in 
contrast to histidine 1401 (Figure 13). In addition, a previously generated model of 
amyloid fibrils of humPrP(108-143), which was generated on the basis of solid-state 
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NMR chemical shifts2, predicted histidine 111 and serine 135 to be in close 
proximity.   
	
Figure 13. Schematic representation of the main regions and characteristics of 
the prion protein. The mutation sites in red correspond to inherited forms of prion 
diseases. Residues 1-22 and 232-240 are cleaved during maturation of the protein. 
Orange boxes mark the location of a-helices in the native structure of PrP (reference 
3). humPrP(108-143) comprises residues 111-138 (green), which are solvent-
protected in amyloid fibrils of humPrP(108-143). 
 
We first asked whether histidine 111 and 140 are in the same 
microenvironment in the free monomeric state. To this end, we performed a pH 
titration of the disordered monomeric humPrP(108-143), which probes the response 
of the two histidine residues to protonation. We changed the pH from 8 to ~2 and 
followed the chemical shift of the two histidines by two-dimensional 1H-1H TOCSY 
(TOtal Correlated SpectroscopY). Figure 14 shows that both histidine residues 
respond in a similar manner as the pH decreases, resulting in a common pKa of 5.8. In 
addition, substitution of histidine 111 by a lysine residue did not affect the pKa of 
histidine 140. The analysis showed that the imidiazole ring of both H111 and H140 in 
the monomeric, unfolded state of humPrP(108-143) has a pKa value close to that 
















Figure 14. H111 and H140 are exposed to the same microenvironment. (A) 
Superposition of a selected region from two-dimensional TOCSY spectra of 
humPrP(108-143) showing cross-peaks of the histidine side-chain protons at 
increasing pH (in different colors). pH values are indicated. (B) Chemical shift change 
of H111 and H140 as a function of pH.  
 
Importance of histidine 111 and 140 for amyloid formation of humPrP(108-143) 
Next, we examined the role of histidine 111 and 140 in amyloid formation of 
humPrP(108-143). To this end, we inserted selected point mutations into the 
humPrP(108-143) sequence and preformed aggregation assays with both the wild-
type and the mutated peptides. Amyloid formation of the peptides was evaluated by 
binding assays using the amyloid-specific dye thioflavin T (ThT) as well as electron 
microscopy (Fig. 15). The measurements showed that replacement of H111 by a 
positively charged side-chain (lysine) inhibited the ability of humPrP(108-143) to 
form amyloid fibrils (Fig. 15A). Moreover, introduction of a negatively charged 
aspartic acid at position 135, which is in direct spatial proximity to the imidazole ring 
of H111 in the amyloid fibril model of humPrP(108-143) (S135D, Fig. 15D), 

































was only slightly longer in the H111K/S135D variant when compared to the wild-type 
protein, while its elongation rate was even faster. Consistent with a charge 
compensation mechanism, a peptide, in which the positive and negative charge at 
positions 111 and 135 were interchanged, was also able to form amyloid fibrils (Fig. 
15C). Notably, the aggregation lag phase of the H111D/S135K variant was roughly 
half of that of the wild-type peptide, suggesting that additional factors, such as 
residues in direct proximity of the introduced mutation, might influence the 
aggregation kinetics of humPrP(108-143). In contrast to these charge effects, 
substitution of H111 by phenylalanine and S135 by alanine had little effect on the 





Figure 15. The protonation state of H111 regulates the aggregation of 
humPrP(108-143). (A-C) Time-dependent ThT-fluorescence intensity during 
incubation of different variants of humPrP(108-143). Panel (A) shows that insertion 
of a positive charge at position 111 (H111K) abolishes fibril formation, while 
neutralizing it with a counteracting negative charge (H11K/S135D) restitutes 
fibrillization. (B) Influence of pH on aggregation of humPrp(108-143). Protonation of 
H111 by lowering the pH to 4.5 prevents fibril formation, while protonation of H140 
only slightly extended the lag phase of aggregation (H111K/S135D pH 4.5). (C) 
Swapping of residues at positions 111 and 135 (H111D/S135K) accelerates 
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slightly changes aggregation kinetics. (E) Estimation of aggregate formation by a 
protein sedimentation assay. (F) Electron micrograph of amyloid fibrils formed by the 
H111K/S135D variant of humPrP(108-143) at pH 4.5. The bar represents 200 nm. 
 
 The finding that replacement of H111 by a lysine blocked aggregation of 
humPrP(108-143) suggested that the protonation state of the imidazole ring of H111 
could be an important regulator of the fibrillization of humPrP(108-143). In order to 
support this hypothesis, we repeated the aggregation of both wild-type humPrP(108-
143) and the H111K/S135D variant at pH 4.5. Because the NMR-based pH titration 
had shown that the pKa value of H111 and H140 is 5.8, the imidazole ring of both 
histidine residues carries a positive charge at pH 4.5. All other ionizable residues, on 
the other hand, should not be strongly affected. Figure 15b shows how the decrease to 
pH 4.5 influenced the aggregation of humPrP(108-143). While wild-type 
humPrP(108-143) rapidly formed amyloid fibrils at pH 7.4, no fibrillization was 
detected for it at pH 4.5 by both ThT-fluroescence intensity (Fig. 15B) and protein 
sedimentation (Fig. 15E). In contrast, H111K/S135D humPrP(108-143) efficiently 
fibrillized at both pH 7.4 and pH 4.5 (Figs. 15B,E and F). Only the duration of the lag 
phase was increased by approximately one hour at pH 4.5, while the elongation rate of 
H111K/S135D humPrP(108-143) was similar at both pH values. Taken together the 
data demonstrate that a positive charge in position 111 is able to block the 
conformational change that is necessary for fibril formation of humPrP(108-143), 
consistent with its location in the solvent-protected core of the amyloid fibril (Fig. 
15D). In contrast, H140 is located outside of the fibril core (Fig. 15D) and does not 




Influence of sequence homology at position 138/139 for seeding of prion 
aggregation 
Particularly important for the transmission of prion diseases between different 
species, is the identity of the residues at position 138 and 139 of the prion protein4. To 
investigate the importance of these residues in the context of the PrP(108-143) 
sequence, we were prepared two additional mutant peptides. One of these peptides 
comprised the sequence of the hamster prion protein, which differs from the human 
one by the substitution of isoleucine 138 and 139 by methionine (Fig. 16A), while in 
the second variant only I138 was replaced by methionine. The M138/I139 residue 
combination is found in the sequence of the mouse prion protein. Because the mouse 
sequence has two additional mutations (M109L and M112V), which were not present, 
we called the peptide “mod-mouse” (Fig. 16A). Both the hamster and mod-mouse 
peptides rapidly aggregated in the absence of any aggregation seeds (cyan and pink 
data points in Fig. A4B), with the hamster peptide having a smaller aggregation lag 
phase.   
Next, we tested if aggregation seeds of either hamster PrP(108-143) or mod-
mouse PrP(108-143) are able to seed the aggregation of only the peptide with the 
identical sequence or also the one, which does not have the same residue types present 
at positions 138/139.  Figure 4B shows that aggregation seeds of both mod-mouse 
PrP(108-143) and hamster PrP(108-143) were able to promote the immediate 
formation of fibrils when exposed to fresh monomer of both hamster and mod-mouse 
PrP(108-143), respectively. The data demonstrate that the difference in sequence in 
position 139 is not enough to prevent seeding of aggregation. This is consistent with 
the structural model of amyloid fibrils of humPrP(108-143) (Fig. 15D), because both 
I138 and I139 are located outside of the structural core, where no tight packing of side 
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chains is present. Because previous experiments have shown that mouse and hamster 
prions do not seed each other5, our data suggest that sequence differences between 
hamster and mouse protein outside of the 138/139 region are more important for the 
species barrier. This could be in particular residues in the core of the β-helix shown in 
Fig. 15D, because this is the most tightly packed region of the amyloid fibrils of 
humPrP(108-143), in which side chains of different molecules are regularly stacked. 
To support this hypothesis, we made use of the fibrils, which we obtained from the 
peptides H111F humPrP(108-143) and S135A humPrP(108-143), as seeds in the 
presence of fresh mod-mouse PrP(108-143) monomer. In this case, the sequence 
differences are located in the center of the amyloid structure of humPrP(108-143) 
(highlighted in orange in Fig. 16A). The aggregation profiles were similar to those of 
the free monomeric peptides, demonstrating that mutations within the amyloid core 
region block the seeding of aggregation by preformed amyloid fibrils (Fig. 16B).  
	
Figure 16. Peptide sequences used for aggregation seeding experiments. (A) 
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outside the solvent-protected fibril core (orange region), the seeding potential is not 
affected. If sequence changes occur within the core, seeding is abolished (B).   
 
Conclusions 
• H111 and H140 share the same microenvironment in the unfolded, monomeric 
state. 
• Residues 111 and 135 are in close proximity in the 3D structure of amyloid 
fibrils of humPrP(108-143) and their interaction is crucial for fibril formation. 
• The protonation state of histidine 111 regulates the aggregation of the highly 
conserved central region of the prion protein. 
• A substantial part of the species barrier is dictated by sequence homology. 
Especially important for the seeding is sequence identity within the most 
protected region of the fibril core of humPrP(108-143) comprised by residues 
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ABSTRACT 
α-synuclein is an abundant presynaptic protein that is important for regulation of 
synaptic vesicle trafficking, and whose misfolding plays a key role in Parkinson's 
disease. While α-synuclein is disordered in solution, it folds into a helical 
conformation when bound to synaptic vesicles. Stabilization of helical, folded α-
synuclein might therefore interfere with α-synuclein induced neurotoxicity. Here we 
show that several small molecules, which delay aggregation of α-synuclein in 
solution, including the Parkinson's disease drug selegiline, fail to interfere with 
misfolding of vesicle-bound α-synuclein. In contrast, the porphyrin phtalocyanine 
tetrasulfonate directly binds to vesicle-bound α-synuclein, stabilizes its helical 
conformation and thereby delays pathogenic misfolding and aggregation. Our study 
suggests that small-molecule mediated stabilization of helical vesicle-bound α-





Parkinson’s disease is the second most common neurodegenerative disease. It is 
characterized by specific movement disturbances and affects about 1% of the 
population above 60 years1. Pathologically, Lewy bodies constitute the hallmark of 
the disease2. Lewy bodies are intraneuronal aggregates formed by misfolded species 
of the presynaptic protein α-synuclein (αSyn), as well as a multitude of proteins and 
lipids3-7. So far, only symptomatic treatment is available for Parkinson’s disease and 
related synucleinopathies. Though the normal function of αSyn is still a matter of 
debate, recent evidence suggests that αSyn is important for regulation of synaptic 
vesicle trafficking and neurotransmitter release via SNARE-complex interaction1,8-10.  
Under physiological conditions, αSyn is found in equilibrium between a free 
monomeric species, which samples a large ensemble of dynamic conformations11-13, 
and a membrane-bound α-helical structure14-19. αSyn preferentially interacts with 
acidic phospholipids20 where it folds into a single continuous helix extending up to 
approximately residue 10021,22. In line with the membrane-induced folding of αSyn, 
two antiparallel, surface-bound helices are formed in the presence of detergent 
micelles8,23,24. When αSyn is bound to vesicles, the highly aggregation-prone NAC 
(non-amyloid component) region (residues 61-95), is in an α-helical conformation and 
acts as a membrane sensor25. Since the NAC region is important for initiating αSyn 
misfolding and forms the core of amyloid fibrils26, stabilization of the helical, vesicle-
bound conformation of αSyn might interfere with pathogenic aggregation. 
Increasing evidence indicates that the most toxic species of αSyn are soluble 
oligomeric aggregation intermediates10,27-29. The search for small chemical 
compounds that interfere with the aggregation of unfolded, monomeric αSyn into 
toxic oligomers and fibrils has therefore been intensively pursued using a wide array 
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of in vitro and cellular systems as well as animal models of Parkinson’s disease30-37. 
In contrast, little is known about inhibition of αSyn aggregation in the physiological 
environment of a vesicle. Indeed, interaction with membranes does not inhibit the 
potentially pathological process of αSyn aggregation, but can even promote it20,38. 
Moreover, perturbation of the membrane integrity by αSyn, potentially resulting in 
formation of membrane pores, was suggested to cause neuronal death39. 
Here, we demonstrate that several small molecules that were previously shown 
to delay aggregation of soluble, disordered αSyn, are not able to inhibit aggregation of 
vesicle-bound αSyn. In contrast, the polyphenol phtalocyanine tetrasulfonate (PcTS) 
directly binds to vesicle-bound αSyn, stabilizes its helical conformation and inhibits 
misfolding and aggregation. We further show that PcTS prevents inclusion formation 
and toxicity in a cell model of αSyn aggregation. Thus, our study opens novel 
possibilities for interfering with αSyn misfolding and neurotoxicity in its 
physiological environment. 
Results 
PcTS stabilizes the helical structure of lipid-bound αSyn. A multitude of organic 
compounds from different chemical classes were shown to modulate aggregation of 
αSyn in solution30-33,40. This includes the polyphenols curcumin, baicalein and 
epigallocatechin gallate (EGCG), the drug selegiline, which is used for treatment of 
early-stage Parkinson's disease, and the porphyrin PcTS (Fig. 1a). In agreement with 
previous studies, curcumin, baicalein, and EGCG inhibited almost completely the 
formation of αSyn fibrils in solution when used at a 15:1 compound-to-protein ratio 
(Supplementary Fig. 1). Selegiline and PcTS reduced ThT staining to a smaller degree 





Figure 1 | A small organic molecule stabilizes helical, vesicle-bound αSyn and 
inhibits its aggregation. (a) Chemical structure of PcTS, selegiline, curcumin, 
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baicalein and EGCG. (b,c) Circular dichroism spectra of αSyn before (b) and after 
incubation for 10 days in aggregation-prone conditions (c), both in the absence and 
presence of a 15:1 excess of PcTS (red), selegiline (green), curcumin (blue), baicalein 
(light blue) and EGCG (orange). The lipid-to-protein molar ratio was 125:1. In the 
presence of PcTS, the α-helix content was ~41% and less than 10% of β-structure was 
formed after ten days of incubation in aggregation-prone conditions. (d-f) α-helix (d) 
and β-sheet (e) content together with ThT fluorescence (f) aggregation kinetics of 
vesicle-bound αSyn. The control did not contain any small molecule. Error bars 
represent ± standard deviation from the mean of at least 3 different experiments. As 
the C-terminal domain remains disordered in vesicle-bound αSyn13, the maximum α-
helical content is ~70%. In wt αSyn fibrils, the central domain (approximately 
residues 38-96 with some loops) is converted into β-structure60, corresponding to a β-
structure content of ~40%. (g-j) Electron micrographs of fresh (g,h) and aggregated 
(i,j) αSyn/SUV samples: control (g,i) and PcTS (h,j). The white bar represents 500 
nm.  
 
Next we tested if curcumin, selegiline, baicalein, PcTS and EGCG interfere 
with the binding and folding of αSyn on the surface of small unilamellar vesicles 
(SUVs)21. To address this question, we formed SUVs from a 1:1 mixture of 1-
palmitoyl-2-oleoyl phosphatidylcholine (POPC) and 1-palmitoyl-2-oleoyl 
phosphatidic acid (POPA). NMR spectroscopy showed that selegiline, baicalein and 
EGCG interact with POPA/POPC liposomes (Supplementary Fig. 2). Nevertheless, 
none of the compounds impaired vesicle-binding of αSyn and its folding into an α-
helical conformation even at a 15-fold excess of compound with respect to αSyn (Fig. 
1b and Supplementary Fig. 3). 
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Are the small molecules able to modulate the aggregation of αSyn in the 
presence of vesicles? To address this question, αSyn was subjected to aggregation-
promoting conditions (37 ºC, constant stirring) for ten days in the absence and 
presence of the small molecules. When no compound was present, the α-helical 
content of αSyn decreased from ~70% to below 25% (Fig. 1b,c,d). In parallel, β-
structure was formed, the sample stained for the amlyoid-dye thioflavin T (ThT) and 
electron microscopy revealed fibrillar structures (Fig. 1c,e,f,i), consistent with 
previous results1,34,41. Despite its strong anti-aggregation capacity toward soluble 
αSyn (Supplementary Fig. 1), curcumin did not block the transition from α-helix to β-
structure of vesicle-bound αSyn nor the formation of amyloid fibrils (Fig. 1c,d,e,f and 
Supplementary Fig. 4). Selegiline, baicalein and EGCG also did not interfere with the 
loss of α-helical structure (Fig. 1c,d), although samples aggregated in the presence of 
EGCG and baicalein stained only weakly for ThT, probably as a result of competition 
with the compounds for binding sites on αSyn fibrils (Fig. 1f). The amount of fibrils 
observed in EM micrographs in the presence of EGCG was small (Supplementary 
Fig. 4), indicating that EGCG directs αSyn into off-pathway aggregates both in 
solution32 and in the presence of vesicles. Curcumin, baicalein, selegiline and EGCG 
were used at a 15:1 compound-to-protein ratio. The reported apparent binding 
constants of curcumin and baicalein to αSyn are 10 µM and 500 nM, respectively, 
while selegiline and EGCG do not bind to monomeric αSyn, but interact with 
oligomeric species30,31,33,42,43. 
 In contrast to curcumin, selegiline, baicalein and EGCG, no ThT signal was 
detected after ten days of incubation of vesicle-bound αSyn when PcTS was present 
(Fig. 1f). In addition, EM micrographs were free of fibrillar structures and the vesicle 
morphology appeared unmodified (Fig. 1h,j). Quantification of the secondary 
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structure indicated that even after 10 days of incubation in aggregation-prone 
conditions the α-helix content remained at ~41% and less than 10% of β-structure was 
formed (Fig. 1c,d,e). Thus, PcTS is able to stabilize the helical, membrane-bound 
conformation of αSyn and inhibit its aggregation in the presence of vesicles. PcTS 
also inhibited αSyn aggregation in the presence of large unilamellar vesicles (LUVs) 
(Fig. 2). Experiments at different αSyn:compound ratios further showed that a 5:1 but 
not a 1:1 PcTS:αSyn ratio was sufficient to inhibit amyloid formation (Supplementary 
Fig. 5).  
 
Figure 2 | Influence of selected small molecules on fibril formation of αSyn in the 
presence of a ~12.5 mM concentration of large unilamellar vesicles (LUVs). Fibril 
formation kinetics in aggregation prone conditions (37 °C with stirring). The 
concentration of αSyn was 100 mM. 15-fold excess of compound over protein was 
used. The final DMSO concentration was 1% of the total volume. Average values of 
at least 3 different samples. Error bars represent ± standard deviation from the mean 
of at least 3 different experiments. 
PcTS releases the NAC region from the vesicle surface. To obtain insight into the 
mechanism of the stabilization of the α-helical structure of membrane-bound αSyn by 
PcTS we used solution NMR spectroscopy. Although the slow tumbling rate of 
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vesicles induces lipid-bound αSyn to exhibit dynamic properties that hamper its direct 
observation by solution NMR, exchange with the NMR-visible, lipid-free form allows 
residue-specific access to the properties of the membrane-bound state24. We probed 
this exchange process using two-dimensional 15N-1H heteronuclear single quantum 
coherence (HSQC) experiments of 100 µM αSyn in the presence of 12.5 mM SUVs 
(1:125 protein-to-lipid ratio). In line with previous studies24, the NMR signal 
intensities of the 100 N-terminal residues were strongly decreased compared to free 
αSyn (Fig. 3a red spectrum; 3b, red line). The observed signal originates from 
unbound αSyn, as the bound protein does not contribute24. In the C-terminal region, 
the NMR resonances had a comparable intensity as in the free state, indicating that 




Figure 3 (previous page) | PcTS binding partially releases αSyn’s NAC region 
from vesicles. (a) Selected region of 2D 15N-1H HSQC spectra of free (left) and 
vesicle-bound αSyn (right) in the absence (red) and presence of a 15-fold excess of 
PcTS (black). NMR signals of residues in the NAC region are significantly broadened 
when in contact to liposomes (right panel). Upon PcTS addition (black spectrum), 
cross-peaks of these amino acids gain in intensity, indicating a partial release from the 
vesicle surface. (b) Quantification of NMR signal intensities along the αSyn sequence 
when bound to SUVs in the absence (red line) and the presence of a 15-fold excess of 
PcTS (black bars). Signal intensities (I) were normalized by the values observed for 
αSyn in the absence of SUVs (I0). The lipid-to-protein molar ratio was 125:1. White 
color marks the aggregation-prone NAC region (residues 61-95). Note that when 
residues are no longer in contact with liposomes, they become "visible" to solution 
NMR. (c) Quantification of the signal intensity difference upon addition of PcTS. The 




Figure 4 | Influence of mutations, buffer composition and lipid composition on 
binding of αSyn to vesicles. (a) Mean residue ellipticity of αSyn variants for 
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increasing lipid-to-protein ratios. When not indicated otherwise SUVs were composed 
of a 1:1 mixture of POPA:POPC and the buffer system was 5 mM HEPES buffer, 10 
mM NaCl, pH 7.4. In addition, data for the wild-type protein in 5 mM sodium 
phosphate buffer, 10 mM NaCl (red) are shown. The Y39A, F94A and Y39A/F94A 
mutations do not attenuate αSyn binding to liposomes (a; green, blue and cyan, 
respectively). (b-d) Quantification of NMR signal intensities along the αSyn sequence 
when bound to SUVs in the absence (red line) and the presence of a 15-fold excess of 
PcTS (black bars). Signal intensities (I) were normalized by the values observed for 
αSyn in the absence of SUVs (I0). (b) When compared to Fig. 3b, the same molar 
ratios of αSyn:SUVs:PcTS were used, but at an overall 5-fold decreased concentration 
(2.5 mM SUVs, 20 µM αSyn, 300 µM PcTS). The lipid-to-protein molar ratio was 
125:1. (c) NMR signal broadening profile in the presence of vesicles composed of 
DOPE, DOPS and DOPC at a molar ratio of 5:3:2. Because of the lower affinity of 
αSyn to DOPE:DOPS:DOPC vesicles (when compared to POPA:POPC vesicles) a 
higher lipid-to-protein ratio was used. (d) Effect of PcTS on the liposome-induced 
NMR signal broadening profile of αSyn in a 50 mM sodium phosphate buffer 
containing 10 mM NaCl, pH 7.4. SUVs were composed of a 1:1 mixture of 
POPA:POPC. NMR measurements were performed at 15 °C. 
 
Upon addition of 1.5 mM PcTS (15:1 compound-to-protein ratio), the cross-
peaks of residues in proximity to Y39 and F94 as well as at the N-terminus were 
further attenuated and shifted (Fig. 3a,b,c and Supplementary Fig. 6). The intensity 
decrease and chemical shift changes are caused by the binding process and were 
previously observed upon addition of PcTS to soluble αSyn34. It shows that PcTS is in 
solution and can bind to the residual unbound protein. In contrast, residues within the 
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NAC region (residues 61-95) gained approximately 20 to 30% of intensity (Fig. 3a, 
black spectrum; Fig. 3b, black bars; Fig. 3c). In addition, at higher lipid-to-protein 
ratios, when no NMR signals are observed for the N-terminal 100 residues, addition 
of PcTS led to the appearance of resonances from the NAC region (Supplementary 
Fig. 7). Thus, PcTS promotes a faster exchange of the NAC region between the 
vesicle-bound and free state, making NAC residues "visible" in the NMR spectrum. 
Using a different buffer system (50 mM phosphate, pH 7.4) and/or different liposome 
composition (DOPE, DOPS and DOPC in a 5:3:2 ratio) yields the same behavior in 
which the NAC region of αSyn is released from its interaction with the membrane 
(Fig. 4). Also, the concentrations of PcTS used here are not sufficiently large to 
interfere with the formation of liposomes (Supplementary Fig. 8). In contrast to PcTS, 
addition of curcumin, selegiline, and baicalein did not change the NMR signal 
intensity profile of αSyn in the presence of POPC/POPA vesicles (Fig. 5). EGCG 
further reduced the NMR signal intensity of residues 1-130, consistent with the 
EGCG-mediated conversion of αSyn molecules, which are not bound to the vesicles, 
into off-pathway oligomeric species. 
 
Interaction with Y39 and F94 drives NAC-domain release. It was previously 
shown that PcTS directly binds to monomeric, soluble αSyn34. The interaction is 
driven by aromatic stacking with F4, Y39 and F94. In order to study the importance 
of Y39 and F94 for binding of PcTS to membrane-bound αSyn, we generated the 
αSyn mutants Y39A and F94A, as well as the double mutant Y39A/F94A. The SUV-
induced intensity profiles of the mutants were similar to that of wild-type (wt) αSyn 
(Fig. 6a-c), indicating a similar affinity and mechanism of membrane binding. This 
was confirmed by determination of a dissociation constant of ~60±15 µM in all cases 
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(assuming a one-site binding model; Fig. 5a). It also suggests that Y39 and F94 are 
not important for anchoring αSyn to POPA/POPC vesicles, consistent with the 
observation that Y39 is primarily water exposed when αSyn is bound to vesicles44.  
 
Figure 5 | Interaction of selegiline, EGCG, curcumin and baicalein with soluble 
and vesicle-bound αSyn. (a) Quantification of NMR signal intensities along the 
αSyn sequence when bound to SUVs in the absence (red line) and the presence of a 
15-fold excess of selegiline, EGCG, curcumin and baicalein (black bars). Signal 
intensities (I) were normalized by the values observed for αSyn in the absence of 
SUVs (I0). The lipid-to-protein molar ratio was 125:1. The ratio of NMR signal 
intensities of free (in the absence of SUVs) αSyn in the presence and absence of the 
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respective compound are shown in light blue. (b) Chemical shift differences for free 
αSyn in the absence and presence of the compounds. EGCG causes intensity and 
chemical shift changes due to its binding to monomeric αSyn and conversion of αSyn 
into off-pathway oligomers. The dashed lines represent the intrinsic error for the 
chemical shift measurement.   
 
We then added PcTS to the αSyn variants in complex with vesicles. In the 
presence of a 15-fold excess of PcTS, NMR signal intensities in the NAC region of 
the Y39A mutant increased by about 15% (Fig. 6a), while the wt protein regained 
about 20-30% (Fig. 3b,c). In case of the F94A variant of αSyn, the PcTS-induced 
signal increase remained also below that of wt αSyn and was only slightly larger than 
for the Y39A mutant (Fig. 6b). Notably, simultaneous mutation of Y39 and F94 
abolished the PcTS-induced signal increase in the NAC region (Fig. 6c). Thus, the 
partial release of αSyn’s NAC residues from the membrane-surface is specifically due 
to the interaction of PcTS with Y39 and F94. 
To obtain further insight into the αSyn-membrane interaction, we performed 
15N spin relaxation measurements. Previous experiments had shown that the exchange 
with the membrane-bound α-helical state enhances the relaxation of the NMR 
resonances of disordered soluble αSyn24,45. Consistent with this finding, addition of 
SUVs increased the transverse 15N spin relaxation rate from ~3 s-1 to ~14 s-1 for 
residues 1-40 and to ~12 s-1 for residues 40-100 (Fig. 6d). In the presence of PcTS, 
relaxation rates in the N-terminal part of wt αSyn remained high, while in the NAC 
region the average 15N transverse relaxation rate decreased from ~12 s-1 to ~7 s-1 (Fig. 
6d,e). The decreased contribution of the vesicle-bound state to the observed spin 
relaxation rate supports a PcTS-induced partial release of the NAC region of wt αSyn 
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from the vesicle surface. In contrast, no PcTS-induced changes in relaxation rates 
were observed for the Y39A/F94A variant of αSyn (Fig. 6e,f), in agreement with the 
importance of Y39 and F94 for PcTS-binding and NAC domain release.  
 
Figure 6 | Y39 and F94 are essential for PcTS-induced membrane detachment of 
αSyn. a-c Residue-specific NMR signal intensities in the αSyn variants (a) Y39A, (b) 
F94A and (c) Y39A/F94A in the presence of SUVs without (red line) and with a 15-
fold excess (black bars) of PcTS. Signal intensities (I) were normalized by the values 
observed for each αSyn variant in the absence of SUVs (I0). The lipid-to-protein 
molar ratio was 125:1. White color marks the aggregation-prone NAC region. In the 
absence of the two aromatic residues Y39 and F94, PcTS does not affect the binding 
of aSyn to vesicles. (d) 15N R2T transverse spin-relaxation rates in wt αSyn in the 
absence of vesicles (blue), the presence of SUVs (red) and after further addition of a 
15-fold excess of PcTS (black). The lipid-to-protein molar ratio was 6:1. In the 
presence of SUVs, the relaxation rates increase at the N-terminus and the NAC region 
due to the exchange with the vesicle-bound state (red). PcTS-induced release of the 
NAC region increases the exchange between free and vesicle-bound αSyn causing a 
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decrease in R2T values (black). (e) 15N R2T rates in the Y39A/F94A αSyn variant. Due 
to the depletion of the binding sites, PcTS does not influence the exchange of this 
αSyn variant with membranes. As in (d), error bars represent curve fitting errors. (f) 
R2T values averaged over residues 1-60 (grey), 61-95 (white) and 96-140 (grey) in 
both wt and Y39A/F94A (mut) αSyn. Values in the absence and presence of PcTS are 
shown by red and black bars. The average value of R2T in free wt αSyn is shown as 
blue horizontal line. Error bars indicate standard deviation. 
 
A distinct aggregation pathway of vesicle-bound αSyn. Next we asked if the PcTS-
mediated inhibition of aggregation of vesicle-bound αSyn (Fig. 1) is connected to the 
PcTS-induced partial release of αSyn’s NAC region from the membrane surface 
(Figs. 3,6). To address this question, we analyzed the influence of PcTS on the 
aggregation of both wt and mutant αSyn in the presence of vesicles (Fig. 7). While 
PcTS completely blocked aggregation of vesicle-bound wt αSyn, the αSyn variants 
were able to form amyloid fibrils in the presence of PcTS (Figs. 1 and 7). Aggregation 
of the Y39A/F94A double mutant in the presence of PcTS even approached the 
aggregation behavior of wt αSyn in the absence of PcTS (Fig. 7), despite the fact that 
its vesicle-induced broadening profile did not differ from that of wt αSyn (Fig. 6c). 
The slower fibrillization rate of the single point mutants when compared to 
Y39A/F94A αSyn (Fig. 7a) is in agreement with a PcTS-induced partial release of the 
NAC region of Y39A αSyn and F94A αSyn from the vesicle surface (Fig. 6a,b). The 
data demonstrate that membrane-attachment of the NAC region is essential for 
aggregation of αSyn in a lipid environment. 
It was previously shown that Y39 is important for αSyn aggregation in 
solution. When Y39 was mutated to alanine, the formation of fibrils was strongly 
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delayed (Fig. 8)34. Given the differences at the micro-environmental level between 
free and vesicle-bound αSyn, we asked if the presence of this aromatic residue at 
position 39 plays a similar role for vesicle-bound αSyn. However, the Y39A mutation 
did not interfere with the aggregation of vesicle-bound αSyn (Fig. 8). The distinct 
aggregation behavior of the Y39A variant of αSyn in solution and when bound to 
vesicles demonstrates that the early stages of aggregation differ drastically between 
the free, disordered and the membrane-bound α-helical αSyn.  
 
Figure 7 | Sequence specificity of the small molecule-mediated inhibition of 
amyloid formation of vesicle-bound αSyn. (a) Fibrillization kinetics of wt αSyn and 
its mutants in the presence of a ~12.5 mM concentration of SUVs. Shown is the 
normalized ThT intensity for increasing times of incubation in aggregation prone 
conditions. The concentration of αSyn was 100 µM and the molar ratio of PcTS to 
protein was 15:1. The blue line shows the fibrillization kinetics of wt αSyn in the 
absence of PcTS. In the presence of PcTS, wt αSyn (black) does not form ThT-
positive fibrils. Removing one aromatic residue decreases the PcTS inhibitory effect 
(green and red lines). Removal of both Y39 and F94 (purple line) abolishes the PcTS-
mediated aggregation inhibition. The circles represent the average ThT intensity of at 
least 3 different experiments normalized against their respective maximum values. (b) 
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ThT fluorescence after six days of aggregation. The error bars represent the standard 
error of at least 3 different samples. 
 
Figure 8 | Fibrillization kinetics of the Y39A mutant of αSyn in solution (black), 
when bound to membranes (red) and after further addition of PcTS (blue). 
Shown is the ThT fluorescence intensity after increasing times of incubation in 
aggregation prone conditions (37 °C with stirring). The concentration of Y39A αSyn 
was 100 µM, that of SUVs ~12.5 mM. While little fibrillization was observed for the 
Y39A mutant of αSyn in solution, it readily aggregates in the presence of SUVs. 
Moreover, the data show that PcTS is capable of decreasing aggregation of vesicle-
bound αSyn through an interaction with F94. Error bars represent the standard error 
for at least three different samples. 
 
PcTS reduces αSyn inclusion formation and cytotoxicity. In order to determine the 
effect of PcTS on αSyn aggregation and αSyn-induced cytotoxicity, we employed a 
previously described cell model46 that leads to protein inclusion formation positive for 
αSyn. Addition of 0.1 and 1 µM of PcTS to H4 cells expressing αSyn did not modify 
inclusion formation. In contrast, treatment with 10 µM PcTS for 48 h decreased the 
percentage of cells with inclusion formation (Fig. 9 a,b) 
 Next we tested if PcTS would also influence αSyn induced cytotoxicity in the 
same cell model. Toxicity was determined 48 h after transfection and start of PcTS 
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treatment by determining the release of lactate dehydrogenase (LDH) into the 
medium. We determined no effect on αSyn toxicity in the vehicle control, but 
observed a drop in LDH release upon treatment with 10 µM PcTS, the same 
concentration that led to inclusion modulation (Fig. 9c).  
 
Figure 9 | PcTS reduces αSyn inclusion formation and cytotoxicity. (a) 
Representative images for αSyn inclusion modulation by 10 µM PcTS in H4 cells. 
Scale bar = 25 µm. (b) Addition of 10 µM to H4 cells expressing αSyn decreases 
inclusion formation. No effect can be observed with lower concentrations of PcTS or 
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vehicle control. (c) PcTS reduces αSyn-induced cytotoxicity. Addition of 10 µM 
PcTS to H4 cells expressing αSyn decreases release of LDH into the medium, an 
indicator for cytotoxicity. No effect could be observed with lower concentrations of 
PcTS or vehicle control. Data represent mean ± standard deviation of four or seven 
independent experiments with P<0.05 with paired, two-tailed student’s t-test and One-
way ANOVA with post-hoc Bonferroni. 
 
Discussion  
αSyn is important for regulation of synaptic vesicle trafficking8 and is found in both 
soluble and membrane fractions of neuronal cells9,16. Consistent with a physiological 
role of the membrane-bound conformation of αSyn, its N-terminal 100 residues have 
a high propensity to bind to negatively charged vesicles and fold into an α-helical 
conformation25,47. At the same time, αSyn can misfold, aggregate and form fibrils 
when it is in contact with phospholipid vesicles38 pointing also to a pathological role 
of membrane-bound αSyn.  
Aggregation of vesicle-bound αSyn, which has a low surface coverage when 
compared to other peripheral membrane proteins such as apocytochrome c44, was 
suggested to occur through a two-state process48. Initially, the N-terminus and the 
NAC domain of αSyn are bound to vesicles in an α-helical conformation. Aggregation 
is initiated by insertion of hydrophobic residues of the NAC domain into the 
membrane leading to an intermediate conformation. This intermediate conformation is 
at least partially inserted into the lipid bilayer and is characterized by partial unfolding 
of the helical conformation and formation of elements of β-structure48. A further step 
during aggregation of vesicle-bound αSyn is oligomerization through the NAC 
domain, which occurs either parallel to the unfolding of the helical conformation or 
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subsequent to it48, followed by formation of amyloid fibrils. Amyloid fibrils formed in 
the presence of POPC/POPA vesicles closely resembled those formed in the absence 
of lipid vesicles and were immersed in a network of vesicles with substantially 
perturbed morphology48. A direct attachment of fibrils to SUVs is also supported by 
studies on the islet amyloid polypeptide, which showed that its fibrils line the surface 
of distorted phospholipid vesicles, in agreement with the notion that fibril growth at 
the membrane and membrane damage are physically connected49.	Our data support 
the above aggregation model and reveal a way to interfere with aggregation of αSyn 
in contact with synaptic vesicles. PcTS directly binds to Y39 and F94 of membrane-
bound αSyn. This interaction partially releases the NAC domain from the membrane 
surface (Figs. 3, 6) such that the helical conformation in the NAC region is less prone 
to membrane-assisted unfolding, subsequent oligomerization and amyloid formation 
(Figs. 1, 7, 10).  
Inhibition of αSyn aggregation in the membrane-bound state is specific to 
PcTS, since several other small molecules, which inhibit aggregation of αSyn in 
solution, did not stop aggregation in the lipid environment (Fig. 10). This suggests 
that compounds such as curcumin and baicalein primarily act at the stage of soluble 
oligomer formation, while their affinity to monomeric αSyn is low. In addition, 
baicalein, selegiline and EGCG interact with liposomes (Supplementary Fig. 2) 
further decreasing their efficacy in a lipid environment.	PcTS, on the other hand, does 
not bind to liposomes and readily interacts with monomeric αSyn both in the absence 
and presence of lipid membranes. The green tea polyphenol EGCG also attenuated the 
formation of β-sheet rich amyloid fibrils in the presence of vesicles, in agreement 
with its ability to bind to monomeric polypeptides32. However, in contrast to PcTS, 
EGCG was not able to stabilize the helical, membrane-bound conformation of αSyn 
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(Fig. 1). Instead it directs αSyn into heterogeneous off-pathway oligomers32. It has 
also been demonstrated that while EGCG is able to prevent the formation of 
aggregates and to disrupt already formed fibrils of the islet amyloid polypeptide when 
used in solution, its ability to do so in a phospholipid interface is greatly diminished50. 
Whether this is the result of a less accessible protein interface for the compound, 
membrane binding of EGCG or stabilization of the fibril by its interaction with 
phospholipids is unknown. The effectiveness of small molecules to inhibit 
aggregation of vesicle-bound proteins might also be related to changes in the 
aggregation pathway of the protein in the presence of lipids. Whatever the case, the 
combined data suggest that compounds, which show strong anti-aggregation 
properties in solution, do not necessarily have the same efficacy when used in the 
presence of lipids. Thus, it is important to assess the anti-aggregation properties of 
small molecules in a lipid environment, in particular as disruption of the cellular 
membrane might be a key mechanism how fibrillar/oligomeric species of αSyn 
acquire their neurotoxic properties. 
The fact that Y39 is essential for aggregation of αSyn in solution34 but not 
when bound to membranes (Fig. 8) shows that the very first stages of aggregation in a 
membrane environment are different from those that happen in solution. In solution 
the lack of an aromatic side chain in position 39 would interfere with the self-
assembly process of aggregation, whereas in a membrane environment aggregation 
initially depends on the insertion of hydrophobic residues within the NAC domain and 





Figure 10 | Small molecule-mediated stabilization of helical vesicle-bound αSyn 
inhibits pathogenic aggregation. PcTS directly binds to vesicle-bound αSyn, 
stabilizes its helical conformation and delays misfolding and pathogenic aggregation. 
In contrast, EGCG, baicalein, curcumin and selegiline inhibit the conversion of the 
disordered monomeric αSyn into amyloid fibrils, but are not able to stabilize helical, 
vesicle-bound αSyn. Residues 1-60, 61-95 and 96-140 of αSyn are shown in orange, 
green and purple. Please see text for further details. 
 
PcTS inhibits the aggregation of prion proteins and has been investigated for 
its in vivo prophylactic and therapeutic effects in scrapie disease42. Inhibition of 
protease-resistant prion aggregates is achieved through stabilization of the native 
globular structure of the prion protein51. Thus, PcTS is able to stabilize well-folded 
protein conformations both in solution (prion protein) and on the membrane surface 
(αSyn; Fig. 1). PcTS is also likely to interfere with aggregation of membrane-bound 
β-synuclein, which has recently been shown to aggregate and cause neuronal loss in 
the rat brain52. β-synuclein binds membranes similar to αSyn and both Y39 and F94 
are conserved53.  
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 Given the wide variety of models that have been proposed to explain the 
misfolding and aggregation of αSyn, the role of membrane interaction has generated 
mixed viewpoints. These range from the complete stabilization of the "native state" of 
αSyn and inhibition of aggregation upon binding of αSyn to vesicles9,16,17,54 to the 
formation of damaging pore-like oligomers formed only in the presence of 
membranes39. As part of these complex processes, αSyn maintains an equilibrium 
between a free and membrane-bound state and – under stress conditions – is prone to 
form soluble oligomers and fibrils. However, our study suggests that the mechanism 
by which αSyn aggregates is very different when it is bound to vesicles than when it 
is free in solution. We also demonstrate that the detachment of the NAC domain of 
αSyn from the vesicle surface greatly delays its aggregation and, to the best of our 
knowledge, this is a unique effect of PcTS. The importance of membrane attachment 
of the NAC domain for αSyn aggregation is consistent with a recent study, which 
showed that the NAC domain acts as a sensor of lipid properties and determines the 
affinity of αSyn membrane binding25. Because the anti-aggregation effect of PcTS is 
much stronger for vesicle-bound αSyn than soluble, disordered αSyn, it is likely that 
PcTS reduces αSyn inclusion formation and cytotoxicity through binding to 
membrane attached αSyn. Our study therefore suggests that small molecule-mediated 
stabilization of the helical membrane-bound state of αSyn provides unique 
opportunities for inhibiting misfolding and pathogenic aggregation of αSyn in the 
physiological environment of a synaptic vesicle. Detailed knowledge about the 
structural basis of αSyn aggregation, together with a screening procedure for small 
molecules that is targeted to helical vesicle-bound αSyn, promises new ways to 





Expression and Purification of αSyn Variants. pT7-7 plasmid encoding for human 
wt αSyn was kindly provided by the Lansbury Laboratory, Harvard Medical School, 
Cambridge, MA. A codon replacement was performed for residue Y136 (TAC to 
TAT) to avoid codon usage problems55. The resulting construct was then used as the 
template for mutagenesis reactions. Mutations were performed by using the 
QuikChange II site-directed mutagenesis kit (Stratagene) and verified by DNA 
sequencing. Plasmids containing αSyn variants were expressed in Escherichia coli 
BL21 (DE3) cells. Protein expression and purification was performed as previously 
described56. For production of 15N-labeled proteins, M9-minimal medium 
supplemented with 15NH4Cl (Cambridge Isotope Laboratories) was used. 
 
Preparation of Unilamellar Vesicles. 1-palmitoyl-2-oleoyl phosphatidylcholine 
(POPC) and 1-palmitoyl-2-oleoyl phosphatidic acid (POPA), 1,2-dioleoyl-sn-glycero-
3-phosphoethanolamine (DOPE), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine 
(DOPS) and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) were obtained from 
Avanti Polar Lipids. For vesicle formation, a 1:1 ratio of POPC:POPA or a 5:3:2 ratio 
of DOPE:DOPS:DOPC was dissolved in a 4 ml mixture of chloroform/methanol (1:1 
vol/vol), followed by evaporation of all solvents under a stream of N2 gas and 
lyophilized overnight. The resulting lipid film was hydrated in 50 mM HEPES, 100 
mM NaCl, pH 7.4 or in 50 mM Na-phosphate buffer (pH 7.4), 100 mM NaCl to 
obtain a total lipid concentration of 12.5 mM. For preparation of SUVs, the 
suspension was sonicated at 37 kHz (four times for 10 min with five min breaks at 
room temperature or until the sample was transparent) in a glass tube. SUVs were 
isolated by ultracentrifugation at 55,000 rpm in a Beckman TLA 100.3 rotor for 2 
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hours at 298 K. The isolated SUVs had a hydrodynamic diameter of 35 ± 10 nm 
according to dynamic light scattering. LUVs were prepared following the same 
procedure but with only two rounds of sonication and no ultracentrifugation step. 
Dynamic light scattering estimated the hydrodynamic diameter of the LUVs as 105 ± 
25 nm.  
 
Aggregation of Vesicle-Bound αSyn. PcTS was purchased from MP Biomedicals 
(MP Biomedicals S.A. Heidelberg, Germany). Selegiline, curcumin, baicalein and 
EGCG were purchased from Sigma (Sigma-Aldrich Chemie GmbH, Schnelldorf, 
Germany). 
SUVs and LUVs were mixed with purified αSyn variants at a 125:1 molar 
ratio of phospholipid to protein in 50 mM HEPES, 100 mM NaCl pH 7.4, 0.02% 
sodium azide (with final concentrations of 12.5 mM of phospholipids and 100 µM for 
αSyn). All compounds were solubilized in a 500 mM stock solution of dimethyl 
sulfoxide (DMSO) and added to the working solution for final concentrations of 0.1, 
0.5 and 1.5 mM (giving 1:1, 5:1 and 15:1 compound to protein ratios). Subsequently, 
samples were subjected to aggregation-prone conditions (37 ºC ~300 rpm) in low 
binding protein™ 1.5 ml Eppendorf tubes over a period of 10 days. After different 
incubation times, a 20 µl aliquot of the sample was mixed with 1 ml of a 100 mM 
ThT solution. Fluorescence emission was measured between 460 and 600 nm on a 
Varian Cary Eclipse fluorescence spectrophotometer (Agilent Technologies) with 
excitation wavelength of 442 nm at 20 ºC. The averaged data points were fitted to a 




CD Spectroscopy. Far UV-CD measurements were performed at 20 °C on a 
Chirascan (Applied Photophysics, UK) circular dichroism spectrometer, using a 
protein concentration of 10 µM in a quartz cuvette with 0.1 cm light-path. For vesicle-
bound αSyn, SUVs or LUVs were added to a final concentration of 1.5 mM. Each 
experiment was repeated at least twice. Baseline correction was performed with the 
same buffer. Data were expressed as mean residue ellipticity (degree cm2 dmol–1). 
Estimation of secondary structure content was performed by neural-network analysis 
using the program K2D available at the DichroWeb server57. 
 
NMR Spectroscopy. NMR samples contained 0.1 mM 15N-labeled wt or mutant αSyn 
in 50 mM HEPES buffer, 100 mM NaCl, pH 7.4 or 50 mM Na-phosphate buffer, 100 
mM NaCl at pH 7.4 and 90% H2O/10% D2O. NMR experiments were recorded on a 
Bruker Avance 600 MHz spectrometer. The temperature was set to 15 °C. Data 
processing was performed using the software packages Topspin (Bruker) and CCPN 
Analysis58. 
To probe the binding of αSyn variants to vesicles, 2D 15N-1H HSQC spectra 
were recorded in the presence of either 12.5 mM SUV or LUVs. The same stock 
solution of compounds in DMSO was used for the NMR experiments in the same 
ratios, so the final DMSO concentration never surpassed 1% of the total volume.  
15N-1H HSQC amide cross-peaks affected during compound addition were 
identified by comparison of their chemical shift values with those of the same cross-
peaks in the data set of samples lacking the compound. Perturbations in the chemical 
shift values for 1H and 15N were calculated as [(Δδ1H)2 + (Δδ15N/10)2]1/2. Intensity 
profiles (I/I0) were obtained by comparing intensities of 15N-1H HSQC cross-peaks 
observed in the presence (I) and absence (I0) of compound.  
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15N TROSY experiments for R2T measurement (modified from59) were 
recorded at 30 °C on a Bruker 600 MHz spectrometer as interleaved experiments with 
six T2 delays (10, 40, 80, 150, 250 and 400 ms). Samples contained 250 µM protein 
and 1.5 mM SUVs (1:6 protein-to-lipid ratio) in 50 mM HEPES buffer, 100 mM 
NaCl at pH 7.4 with 10% D2O. Single exponential decay curves were fitted to the 
signal intensity of each cross-peak throughout the different delay times with the 
function y=Ae(-Bx) + C  , where B is the R2T value. Error bars represent the fitting 
errors.  
 
Transmission Electron Microscopy. A solution containing protein was applied to 
glow-discharged carbon coated grids and stained with 1% uranyl acetate. Images were 
taken in a Philips CM120 electron microscope (Philips Inc.) at a defocus of 2.3 µm 
using a TemCam 224A slow scan CCD camera (TVIPS, Gauting, Germany). 
 
Cell culture and transfection. H4 neuroglioma cells were maintained at 5% CO2 and 
37° C in Optimem medium (Gibco) supplemented with 10% Fetal Calf Serum and 1% 
Penicillin Streptomycin. One day prior to transfection cells were seeded in 24-well 
plates. Cells were transiently transfected with αSyn using Metafectene (Biontex) 
according to manufacturer’s instructions. PcTS compound in DMSO was added in 
concentrations of 100 nM, 1 µM and 10 µM to the cells. αSyn expressing cells were 
treated with DMSO to exclude vehicle effects. 
 
Immunocytochemistry. Cells were fixed with 4% Paraformaldehyde (PFA) in PBS 
48 hours after transfection and start of PcTS treatment. For permeabilization cells 
were subsequently treated with 0.1% Triton X-100 and blocked with 1.5% Bovine 
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Serum Albumin (BSA) in PBS. Cells were then incubated with anti αSyn antibody 
(BD  610787, 1:2000) either 4 hours at room temperature or overnight at 4° C and 3 
hours in Alexa Fluor donkey anti-mouse 555 (Invitrogen A31570, 1:2000). Cells were 
further stained with Hoechst (Molecular Probes 33258) for 5-10 minutes. Images were 
captured using a Leica DMI 6000B. 
 
LDH activity. LDH activity was measured via release of LDH into the culture 
medium with the Cytotoxicity Detection Kit (LDH) (Roche). Basic LDH release was 
measured in non-transfected cells, total LDH release was measured by cell lysis in 2% 
Triton X-100. Absorbance was measured with the Infinite M200 PRO (Tecan) plate 
reader at 490 nm. Experimental values were calculated in percentages of total LDH 
release and normalized to tranfection with SynT without treatment. Statistical analysis 
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Supplementary Figure 1 | Influence of selected small molecules on fibril 
formation of disordered αSyn in solution. Fibril formation kinetics in aggregation 
prone conditions (37 °C with stirring). The concentration of αSyn was 100 µM. 15-
fold excess of compound over protein was used. The final DMSO concentration was 
1% of the total volume. Error bars represent ± standard deviation from the mean of at 





Supplementary Figure 2 | Selected region of the 1H NMR spectra of the small 
molecules PcTS, curcumin, selegiline, baicalein and EGCG in the absence (black) 
and presence (red) of SUVs. Upon addition of vesicles, only the resonances of PcTS 
and curcumin remained unperturbed. Selegiline, baicalein and EGCG interact with 
vesicles and therefore show changes in NMR signal position and intensity. The final 
DMSO concentration was 1% of the total volume in 50 mM HEPES buffer, 100 mM 
NaCl, pH 7.4. NMR spectra were recorded at 288 K. Lipid and compound 
















Supplementary Figure 3 | Conformational properties of αSyn prior to 
aggregation. (a) Secondary structure content of 100 µΜ fresh αSyn bound to 12.5 
mM SUVs. Note that addition of a 15-fold excess of any of the compounds did not 
affect the binding of αSyn to SUVs and its vesicle-induced folding into a α-helical 
conformation. (b) ThT fluorescence signal before aggregation. Average values of at 





Supplementary Figure 4 | Electron micrographs of SUV-bound αSyn before (a-d) 
and after incubation for 10 days in aggregation-prone conditions (e-h) in the 
presence of selegiline (a,e), curcumin (b,f), baicalein (c,g) and EGCG (d,h). White 




Supplementary Figure 5 | Influence of the concentration of PcTS on the 
aggregation of membrane-bound αSyn. Shown is the ThT fluorescence intensity 
after 10 days of incubation in aggregation prone conditions (37 °C with stirring). The 
concentration of αSyn was 100 µM, that of SUVs ~12.5 mM. The molar ratio of 
PcTS to protein ranged from 0:1 (no PcTS) to 15:1 (1.5 mM PcTS). Average values 















































Supplementary Figure 6 | The presence of SUVs does not affect the affinity of 
PcTS to αSyn. (a) 15N-1H HSQC spectra of free (left panel) and SUV-bound (right 
panel) αSyn at increasing concentrations of PcTS (from red to blue). (b) Chemical 
shift changes as a function of PcTS concentration for selected residues in the presence 









Supplementary Figure 7 | Residue-specific NMR signal intensity ratios obtained 
from 15N-1H HSQC spectra of 30 µM of αSyn recorded in the absence (I0) and 
presence of 12.5 mM SUVs (I) (~417:1 lipid to protein molar ratio). Signal 
intensity ratios for wt αSyn in the absence (black) and in the presence (green) of PcTS 
are shown. Data for the Y39A/F94A variant of αSyn in the presence of PcTS are 
shown in purple. The concentration of PcTS was 0.45 mM (15:1 compound to protein 
molar ratio). Note that when residues are no longer in contact with liposomes, they 
become "visible" to solution NMR. Thus, even at higher lipid-to-protein ratios PcTS 









Supplementary Figure 8 | Proton NMR spectra show that PcTS does not interact 
with SUVs (left panel). Also, increasing amounts of PcTS do not fall out of solution 
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Background: In human prion diseases, the phenotype is modified by a 
methionine/valine polymorphism at codon 129.  
Results: Prion stop mutants have a conserved amyloid core comprising residue 129.  
Conclusion: The polymorphic residue 129 is buried in the amyloid core structure. 
Significance: The data support a critical role of the methionine/valine 129 
polymorphism in human prion diseases.  
 
Misfolding of the natively alpha-helical prion protein into a beta-sheet rich isoform is 
related to various human diseases such as Creutzfeldt-Jakob disease and Gerstmann-
Sträussler-Scheinker syndrome. In humans, the disease phenotype is modified by a 
methionine/valine polymorphism at codon 129 of the prion protein gene. Using a 
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combination of hydrogen/deuterium exchange coupled to NMR spectroscopy, 
hydroxyl radical probing detected by mass spectrometry, and site-directed 
mutagenesis, we demonstrate that stop mutants of the human prion protein have a 
conserved amyloid core. The 129 residue is deeply buried in the amyloid core 
structure, and its mutation strongly impacts aggregation. Taken together the data 
support a critical role of the polymorphic residue 129 of the human prion protein in 
aggregation and disease.  
Misfolding of the natively alpha-helical prion protein (PrP
C
) into a beta-sheet-rich 
isoform is related to various human diseases such as Creutzfeldt-Jakob disease and 
Gerstmann-Sträussler-Scheinker syndrome collectively known as transmissible 
spongiform encephalopathies (1). The form of disease is determined by two prion 
types (2), which are a cross species phenomenon (3). Prion types are characterized by 
differences in stability against denaturing agents, different proteinase K-cleavage 
sites, and different forms of prion aggregate deposits (3). These differences were 
attributed to distinct prion conformations (4). In humans, a methionine/valine 
polymorphism at codon 129 of the prion protein gene contributes in determining 
disease phenotypes (2). Although both prion types can be formed with each 
polymorphism at codon 129, methionine shows a strong association with prion type 1 
and valine with prion type 2 (5). Homozygosity at this position predominates in 
sporadic Creutzfeldt-Jakob disease, where up to 89% of patients of large 
epidemiological studies had either Met/Met or Val/Val at codon 129 (6). It has also 
been demonstrated that to achieve a more efficient prion transmission in human PrP-
transgenic mice models, both the inoculum and the mouse should bear the same 
amino acid at position 129 (7).  
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Although the high-resolution structures of PrPC from many species are well described 
(8), little is known about the structure of PrPSc. X-ray fiber diffraction showed that 
infectious prions have cross-beta structure, confirming that prions can form amyloid 
(9). Antibody mapping studies suggested that when PrPC is converted into PrPSc, a 
conformational rearrangement occurs in the region comprising residues 90–176 (10). 
Mass spectrometric analysis of hydrogen-deuterium exchange of brain-de- rived PrPSc 
suggested that prion protein conversion involves refolding of the entire region from 
residues 80–90 to the C terminus (11). Electron microscopy of two-dimensional 
crystals of the 27–30-kDa infectious fragment, PrP27–30, suggested that PrP amyloid 
fibrils might consist of stacked trimers of left-handed -helices with the core formed by 
residues 89 –140 (12–14).  
Characterization of PrPSc at high resolution is currently not possible. Therefore, a 
variety of studies have investigated the structure of amyloid fibrils produced in vitro 
from recombinant prion protein. Mass spectrometry-coupled exchange experiments of 
amyloid fibrils of human prion protein (humPrP) comprising residues 90–231 
indicated strong solvent protection in the region encompassing residues 160–230 (15). 
In contrast, for mouse PrP(23–231), residues 24 –98 and 182–212 were protected 
(16). Hydrogen exchange measurements by mass spectrometry and NMR 
spectroscopy of mouse PrP(89–143) bearing a P101L mutation identified a high level 
of protection from solvent exchange for residues 102–109 and 117–136 (17). In 
addition, molecular dynamics simulations provided models for the conformation of 
PrP in prions (18).  
   
Hereditary prion diseases include C-terminally truncated variants of the prion protein, 
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Y145X, Q160X, Y226X, and Q227X, where X indicates the truncation site (see Fig. 
1A). Although a single experiment to transmit human 145stop mutant prions to mice 
failed (19), the stop mutants provide a particularly valuable model for studying 
misfolding of prion protein (20, 21) as they: (i) lack the normally present glycosyl-
phosphatidylinositol anchor and are secreted into the intercellular medium, which 
appears to favor fibrillization and aggregation (21, 22); (ii) show in vivo prion 
deposits in the form of amyloidogenic plaques or plaque-like aggregates, like other 
prion diseases (23); and (iii) aggregate under nondenaturing conditions in vitro (20, 
22). Previously, we showed that the -sheet content is highly similar in amyloid fibrils 
of the Y145X and Q160X prion stop mutants (22), and solid-state NMR spectroscopy 
revealed extended beta-sheet conformation in the 112–140 region (24–26). Here we 
investigated the importance of the polymorphic residue 129 for the formation and 
structure of amyloid fibrils of human prion stop mutants. Using a combination of 
hydrogen/deuterium (H/D) exchange coupled to NMR spectroscopy, hydroxyl radical 
probing detected by mass spectrometry, and site-directed mutagenesis, we 
demonstrate that the valine/methionine residue 129 is deeply buried in the amyloid 
core of the stop mutants, supporting its critical role in aggregation and disease.  
EXPERIMENTAL PROCEDURES  
Protein Expression and Purification—Plasmids encoding Q160X and N174X were 
expressed in Escherichia coli BL21(DE3) by using M9 minimal medium with [1 5 
N]NH4 Cl (1 g/liter) as the only nitrogen source and as required [
13C6]glucose (4 
g/liter), to obtain uniformly 15N- or 13C,15N- labeled protein, and purified according to 
Ref. 27. Variants of humPrP(108–143) with purity exceeding 95% were obtained 
from EZBiolab.  
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Aggregation of Q160X and N174X into Amyloid Fibrils—Aggregation of Q160X and 
N174X was started by transferring protein solutions into a phosphate buffer (50 mM 
potassium phosphate, pH 6.5) (22). The reaction was carried at 25 °C without 
agitation, and fibril formation was monitored using a thioflavin T fluorescence assay.  
Aggregation of humPrP(108 –143)—Variants of lyophilized humPrP(108–143) were 
dissolved at a concentration of 0.35 mM with ice-cold 25 mM Tris buffer, pH 7.5, 
0.02% sodium azide and dialyzed overnight against 500 ml of 25 mM Tris, pH 7.5, 
0.02% sodium azide at 4 °C in a 500–1000-Da molecular mass cutoff dialysis 
membrane. The peptide was filtered through a 0.22- m Millipore filter. Concentration 
was adjusted to 0.15 mM in a 500 µl final volume, and the solution was incubated at 
12 °C in low binding protein 1.5-ml Eppendorf tubes. After different incubation 
times, a 20 µl aliquot of the sample was mixed with 1 ml of the thioflavin T assay 
solution (0.1 mM thioflavin T in 100 mM NaH2PO4, 140 mM NaCl, pH 8.5), incubated 5 
min at room temperature and transferred to a 10 mm cuvette. The fluorescence 
emission was measured between 460 and 600 nm on a Varian Cary Eclipse 
fluorescence spectrophotometer (Agilent Technologies) with excitation at 442 nm at 
20 °C.  
Quantification of Aggregate Formation by UV Absorbance— To have a second 
measure for aggregate formation of different variants of humPrP(108 –143), 
aggregates were collected after 2.7 and 24 h of incubation by centrifugation at 16,000 
g for 30 min at 4 °C. Subsequently, the pellet was resuspended in 100 µl of 25 mM 
Tris HCl, pH 7.5, and diluted in a 1:5 ratio in 7.5 M guanidine hydrochloride, 25 mM 




Electron Microscopy (EM)—The sample was bound to carbon-coated grids and 
stained with 1% uranyl acetate. Pictures were taken at 72,000 magnification at a CM 
120 with a 2048 2048 pixel TemCam (Tietz) in spotscan mode.  
NMR-detected H/D Exchange—Fibrils were collected by centrifugation (10,000 g for 
5 min) and washed 3–4 times with 50 mM phosphate buffer (pH 6.5) to remove 
residual monomeric protein or low molecular weight oligomers. To initiate exchange, 
the pellet was resuspended in D2O buffer (0.1%formic acid in D2O, pD 2.5) and 
incubated at 4 °C for 3 and 7 days. The samples were then immediately frozen in 
liquid nitrogen and lyophilized. For the NMR experiments, lyophilized proteins were 
resolubilized in ice-cold solution of 2 M guanidinium thiocyanate in 50% H2O, 50% 
D2O, pD 2.5, and a series of 
1H,15N heteronuclear single quantum coherence (HSQC) 
spectra was recorded over a period of 24 h to follow the back-exchange process (28). 
NMR spectra were acquired at 278 K on a Bruker Avance 900 MHz spectrometer 
equipped with a 5-mm triple resonance cryogenic probe head. Experiment time was 
23 min, and the dead time for sample preparation and acquisition setup was 15 min. 
NMR data were processed and analyzed using NMRPipe (29). For non resolvable 
residues within the octarepeat region, protection levels were calculated using aver- 
aged intensities. Signals originating from residues Gly-30, Trp-31, Gly-35, Arg-37, 
Tyr-38, Tyr-49, Gly-53, Gly-55, Trp-57, Met-109, Lys-110, Met-112, Leu-125, Ile-
138, and Tyr-145 were overlapping in the denaturing condition. As signal overlap 
might distort the analysis and lead to false protection factors, these residues were not 
included into the analysis. Exchange curves were fitted to Equation 1 using IgorPro 
5.01  
I/I0 =A1+A2 X exp(A3 X t)   (Eq.1)  
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where I0 is the signal intensity observed in the first HSQC spectrum after dissolution, 
and A1–A3 are fitting variables.  
NMR Resonance Assignment—Sequential backbone assignment of humPrP mutants in 
fibril dissolving buffer was obtained from three-dimensional HACANNH, HNCACB, 
and HNN experiments (30, 31) recorded at 278 K on a Bruker Avance spectrometer 
operating at 900 MHz and equipped with a 5-mm triple resonance cryo probe. The 
samples used for resonance assignment contained typically 0.4 mM 13C,15N-labeled 
variant humPrP in 2 M guanidinium thiocyanate, 90% H2O, 10% D2O, pH 2.5. Due to 
severe signal overlap in the octarepeat region, only 89 resonances for 123 non-proline 
residues of human humPrP(23–159) were observed in two-dimensional 1H,15N HSQC 
spectra of the denatured monomer. 64 of these resonances could be assigned 
unambiguously, whereas the rest could only be located to the octarepeat region.  
Measurement of Diffusion Coefficients—The molecular weight of the amyloid fibrils 
was estimated using NMR pulsed field gradient methods experiments (32). 10 mg of 
unlabeled fibrils were placed in a rotor, and diffusion coefficients were measured 
using the LED pulse sequence with bipolar gradients (33). Spectra were recorded on a 
Bruker Avance 900-MHz spectrometer equipped with a 4-mm high-resolution magic 
angle spinning probe. The sample was spun at 7.2 kHz, total diffusion time was D 100 
ms, and gradient pulse length d 3 ms. Sine-shaped gradients were used, and their 
strength was incremented in 16 steps from g 0.07–0.48 G/mm. The diffusion 
coefficients were calculated by fitting the intensity decay curves (see Fig. 1C) with 
the equation  
I/I0  = exp[-D(γdg)
2(D-d/3-t/2)]    (Eq. 2)  
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where is the gyromagnetic ratio of the 1H nucleus, and t 200 s is the delay for gradient 
switching. For molecular weight estimation, 1,4-dioxane (88 Da) and bovine serum 
albumin (66 kDa) were used as internal and external references.  
Mass Spectrometry (MS)— humPrP(108 –143) was probed in the monomeric and 
fibrillar state by chemically generated hydroxyl radicals, as described in Ref. 34. 70 l 
of 50 M sample were added to an Eppendorf tube containing 10 l of 13 mM Fe-EDTA 
(Sigma-Aldrich and Merck, respectively) solution and 10 l of 0.2 M sodium ascorbate 
(Sigma-Aldrich) solution, both in 50 mM Na2HPO4, pH 6.5 buffer. For control 
purposes, a 17 µl aliquot was transferred to 40 µl of quenching buffer (2 M Tris, pH 
7.2, Prolabo). Finally, 10 µl of 3% v/v H202 (Sigma-Aldrich) were added to the Fenton 
mixture to start the reaction. At 10, 60, 150, and 300 s, 17 µl aliquots were removed 
and transferred to new Eppendorf tubes containing 40 l of quenching buffer.  
To disassemble the probed peptides prior to further analysis, samples were dissolved 
in 200 l of acetonitrile. The total volume was reduced to 20 µl. Subsequently, 150 µl 
of 100 mM Tris, 10 mM CaCl2 buffer and 0.5 g of chymotrypsin (Roche Applied 
Science) were added, and digestion was allowed to proceed overnight at 25 °C. The 
digested samples were desalted with C8 (3M) STAGE tips (35).  
Nano-liquid Chromatography Separation and MS Analysis— For LC-MS/MS 
analyses, samples were dissolved in 30 µl of sample solvent (5% v/v acetonitrile, 1% 
v/v formic acid). 5 µl were injected onto a nano-liquid chromatography system 
(Agilent 1100 series, Agilent Technologies) including an 2-cm- long, 150 µm inner 
diameter C18 trapping column in-line with an 15-cm-long, 75 µm inner diameter C18 
analytical column (both packed in-house, C18 AQ 120 Å 5 m, Dr. Maisch GmbH, 
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Ammerbuch, Germany). Peptides were loaded on the trapping column at a flow rate 
of 10 l/min in buffer A (0.1% formic acid in H2O, v/v) and subsequently eluted and 
separated on the analytical column with a gradient of 7.5–37.5% buffer B (95% 
acetonitrile, 0.1% formic acid in H2O, v/v) with an elution time of 37 min and a flow 
rate of 300 nl/min.  
Online electrospray mass ionization-MS was performed with an LTQ-Orbitrap Velos 
instrument (Thermo Scientific), operated in data-dependent mode using a TOP10 
method. MS scans were recorded in the m/z range of 350–1600. The 10 most intense 
ions were selected for subsequent MS/MS. Both precursor ions as well as fragment 
ions were scanned in the Orbitrap. Fragment ions were generated by higher energy 
collision dissociation activation (normalized collision energy 40) and recorded from 
m/z 100. As precursor ions as well as fragment ions were scanned in the Orbitrap, the 
resulting spectra were measured with high accuracy (5 ppm) both in the MS and in the 
MS/MS level.  
Determination of Oxidized Sites—Data analysis was per- formed using MaxQuant 
1.1.1.14 (36). Database search was performed against humPrP(108–143) with 
Andromeda (37) considering a total of 14 variable modifications: hydroxylation (16 
Da) in His, Val, Met, Leu, Tyr, Arg, Pro, Ile, Phe; dioxidation (32 Da) of Met, Tyr, 
Phe; deguanidination (43 Da) in Arg; and ring opening (22) in His. The oxidation 
levels at any given time point were calculated on a per-residue basis. By making use 
of extracted ion chromatograms, obtained with Xcalibur (10 ppm tolerance), the ratios 
of oxidized to nonoxidized peptides in which a specific residue is involved were 
determined according to Ref. 38 and as illustrated below for Met-112  
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 (Eq. 3)  
 
where O indicates the oxidized residue. Because ionization efficiencies of modified 
and unmodified species are similar, but not identical, the results need be interpreted in 
a relative context (i.e. fibrillar versus monomeric states). For quantification of 
peptides that contain several modifications in different combinations that lead to the 
same m/z value (termed isobaric oxidized peptides), we made use of the fact that these 
elute at different retention times from the LC into the mass spectrometer (ranging 
from 1 to 9 min with respect to the non oxidized peptide). To the same purpose, only 
the most abundant charge state of each peptide was considered.  
Error Calculation—Two independently prepared fibril samples and two monomeric 
samples were measured and used for error calculation, and the error informed 
corresponds to the S.E. It should be noted that the sum of the intensities 
corresponding to different combinations of oxidized residues (the case for most 
methionines) lead to higher uncertainties, which stresses the need for the results to be 
interpreted in a relative context.  
RESULTS  
Size Estimation of humPrP(23–159) Fibrils—To characterize the molecular weight of 
humPrP(23–159) fibrils (Fig. 1B), we have used pulsed-field gradient methods (32) 
combined with high-resolution magic angle spinning (Fig. 1C). High-resolution magic 
angle spinning averages out NMR signal broadening caused by inhomogeneity in 
magnetic field anisotropy and thus allows detection of flexible regions in aggregates, 
whereas NMR-based pulsed field gradient methods provide an estimate of the 
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diffusion coefficient of aggregates. To take into account the nonspherical shape of 
fibrils and contribution from rotational diffusion, the equations described by Perrin 
(39) were applied to calculate the corresponding diffusion constant of a spherical 
molecule of the same molecular weight. For this calculation, the average diameter and 
length of the fibrils were estimated from EM micrographs as 15 and 500 nm, 
respectively. Using the Stokes-Einstein relation, the molecular weight of humPrP(23–
159) fibrils was estimated to be in the order of 4 MDa.  
Solvent Protection in the Fibrillar State—The solvent accessibilities of single 
residues in amyloid fibrils (Fig. 2) of the hereditary stop mutant Q160X were probed 
using NMR-detected H/D exchange (40). To allow detection by liquid-state NMR and 
at the same time preserve the H/D exchange pattern, fibrils that had been exposed to 
H/D exchange were rapidly converted to monomers in a 2 M solution of guanidinium 
thiocyanate in 50% H2O, 50% D2O (28). Back-exchange was then monitored in the 
denatured state by a series of two-dimensional 1H,15N HSQC spectra (Fig. 2). 
Neglecting back-exchange before and during the first HSQC after dissolution, the 
intensity ratio is 1.0 for an amide proton, for which the protection level in the fibril is 
50%, and reaches a minimum of 0.5 for an amide proton with a 100% protection level 
in the fibrillar state.  
To allow a residue-specific analysis of the H/D exchange, an assignment of the 
denatured protein in the dissolving buffer was required. Due to severe signal overlap 
in the octarepeat region, 89 distinct resonances for 123 non-proline residues of human 
humPrP(23–159) were observed in two-dimensional 1H,15N HSQC spectra of the 
denatured monomer. Sequence- specific backbone assignment was obtained for 64 of 
these resonances from a set of standard three-dimensional HACANNH, HNCACB, 
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and HNN experiments (30, 31). The rest could only be located to the octarepeat 
region. Based on the sequence- specific resonance assignment, a solvent protection 
map was constructed that revealed back-exchange ratios of more than 1.2 for the 
segments 23–108 and 143–173 (Fig. 3A). In the central domain comprising residues 
109–142, two regions could be distinguished: residues 109–120 and 140–142 with 
intermediate amide proton back-exchange ratios (exchange ratios of 1.0–1.2) and 
residues 121–139 with high protection values (70%). A very similar protection map 
was obtained after 3 instead of 7 days of H/D exchange (Fig. 3A).  
Methionine 129 Is Strongly Protected from Solvent Exchange—Comparison of H/D 
exchange profiles for individual residues (Figs. 2B and 3A) provides further insight. 
Firstly, within the region 109–140, Gly-119 and Ala-120 showed the most 
pronounced increase in signal intensity during the back-exchange process, suggesting 
that a turn may be formed by these residues. Secondly, the striking change in the 
exchange profiles from Ile-139 to His-140 points to a well-defined boundary of the 
fibrillar core. Thirdly, residues 144–156 that form helix1 in the native structure of the 
human prion protein (8) showed high back-exchange ratios, comparable with the 
flexible N-terminal domain and suggesting that the helix1 region is highly solvent-
accessible in amyloid fibrils of humPrP(23–159). Fourth, the polymorphic residue 




FIGURE 1. Amyloid fibrils of humPrP(23–159). A, schematic representation of 
native secondary structure elements and point mutations found in the human prion 
protein. B, electron micrographs of mature fibrils. The white bar indicates 200 nm. C, 
decay of NMR signal intensity under pulsed field gradients recorded for humPrP(23–
159) fibrils (circles), bovine serum albumin (triangles), and 1,4-dioxane (diamonds). 




FIGURE 2. Solvent protection in amyloid fibrils of the Q160X stop mutant. A, 
excerpts from two-dimensional 1H,15N correlation spectra showing changes in signal 
intensities during the back-exchange process. The spectra were taken 1 (top), 6 
(middle), and 24 h (bottom) after the dissolution of fibrils. Sequence- specific 
assignments are indicated. B, changes in signal intensities over time of individual 
residues in the region 111–141 due to back-exchange in the denatured monomeric 
state. Only data for residues that do not overlap in the two-dimensional 1H,15N 
HSQCs are shown.  
A Common Amyloid Core of Human Prion Stop Mutants— To probe the structural 
consequences of residues160QVYY163, which form beta-strand 2 in the native PrP 
structure, we performed H/D exchange on amyloid fibrils of the designed stop mutant 
N174X. The solvent protection map of N174X was very similar to the exchange 
profile of the Q160X stop mutant (Fig. 3B). The high solvent accessibility of residues 
	
	 106	
160–170 suggested that this region is not part of the fibrillar core in the N174X stop 
mutant. In longer peptides, however, more extensive structure could be present in this 
sequence stretch. The combined H/D exchange data indicate that the hydrogen-
bonded core of amyloid fibrils of Q160X and N174X stop mutants of the human prion 
protein comprises residues 121–139, flanked by residues 109–120 and 140–142.  
The Side Chain of the Polymorphic Residue 129 Is Buried in the Amyloid Core—
Next, we investigated the organization of single side chains in the amyloid structure 
of prion stop mutants using hydroxyl radical probing (Fig. 4). Hydroxyl radicals 
covalently modify side chains of solvent-accessible amino acids. The modifications 
induce a mass shift that can be detected by mass spectrometry (41). Measurements 
were performed for the peptide humPrP(108–143) that covers the fibrillar core of the 
stop mutants (Fig. 3) (24–26) and for which amyloid fibrils are morphologically 
similar to those of the stop mutants (Fig. 5). When compared with the stop mutants, 
the humPrP(108–143) peptide has two important advantages: (i) peptides obtained by 
solid-phase synthesis and stored as lyophilized powder are less prone to oxidation of 
methionine residues, a problem previously reported for recombinant prion protein 
(42); and (ii) the disordered N-terminal tail comprising residues 23–107 does not 
modulate the rate of aggregation.  
Hydroxyl radical probing was applied to humPrP(108 –143) in both the disordered 
monomer and the fibrillar state (Fig. 4 and supplemental Fig. S1). Oxidative 
modifications were observed for residues Met-109, Met-112, Tyr-128, Met-129, Leu-
130, Met-134, Arg-136, Pro-137, Ile-138, Ile-139, His-140, and Phe-141 (Fig. 4 and 
supplemental Fig. S2). Other amino acid residues were not modified because of their 
lower reactivity or solvent accessibility. Strikingly, a pronounced reduction in 
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oxidation was observed for the side chains of Tyr-128, Met-129, and Leu-130 in the 
fibrillar state (Fig. 4B). In addition, small differences in oxidation levels were present 
for Ile-138 and Phe-141. No changes in oxidation were observed for the side chains of 
Met-109, Met-112, Met-134, Arg-136, Pro-137, Ile-139, and His-140 despite the fact 
that the backbone amide protons of several of these residues are part of a fibrillar 
beta-strand (24).  
 
 
FIGURE 3. A conserved solvent-protected core in amyloid fibrils of stop mutants 
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of the human prion protein. A, comparison of the H/D protection maps of 
humPrP(23–159) fibrils exchanged in D2O for 3 days (blue) and 7 days (red). R1–R4 
are the octarepeats. Above part of the domain organization of PrpC is shown (strands 
S1 and S2; helix H1; repeats R1-R4). B, H/D protection maps of humPrP(23–159) 
(black) and humPrP(23–173) (gray) fibrils exchanged in D2O for 7 days. In A and B, 
I24h is the signal intensity after 24 h of back-exchange relative to the signal intensity I0 
observed in the first HSQC spectrum after dissolution. I24h/I0 1.0 indicates strong 
protection from exchange. The location of the proteinase K-resistant core is shown by 
a gray bar. Only data for nonoverlapping residues are shown. The inset shows an 
electron micrograph of humPrP(23–159) fibrils.  
Position 129 Is Critical for Aggregation of Human Prion Stop Mutants—The burial 
of the side chain of Met-129 in the fibrillar core suggests an important role of this 
residue for aggregation of the prion protein. To test this hypothesis, we introduced 
point mutations into humPrP(108–143). Removal of the hydrophobic side chain by 
the substitutions M129N and M129D inhibited the aggregation of humPrP(108 –143) 
(Fig. 5). In contrast, substitution of Met-109 by lysine did not have any effect, 
consistent with the location of Met-109 outside of the solvent-protected region (Fig. 3, 
Table 1). Importantly, substitution of Met-129 with valine reduced the lag time of 
fibril formation. Moreover, when mixing humPrP(108–143) with the Val-129 variant 
at a ratio of 1:3, the lag phase of the aggregation was in between that of the two pure 
peptides, whereas at an equal ratio of the two variants, aggregation was retarded when 
compared with the Met-129 variant alone (Fig. 5A). Thus, a 1:1 mixture of Met-129 
and Val-129 humPrP(108–143) aggregates slower than the pure peptides at the same 
total con- centration, suggesting that the two variants are not as active in the 
formation of aggregation nuclei as the pure sequences.  
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The importance of the 129 position for prion aggregation was further supported by 
seeding experiments. After 6 h of aggregation, Met-129 humPrP(108–143) amyloid 
fibrils were fragmented and homogenized with three 5-min sonication cycles. Three 
different volume/volume percentages (0.1, 1, and 5%) were used as seeds on fresh 
preparations of monomeric Met- 129, Asn-129, and Asp-129 peptides. Regardless of 
the seed concentration, there was no seeding effect on either Asn-129 or Asp-129 
peptides, whereas the Met-129 seed on Met-129 fresh monomer completely removed 
the nucleation phase (Fig. 5D).  
DISCUSSION  
Biochemical analyses of aggregated prion protein in patients with a stop codon 
mutation suffering from a prion disease have shown that the protein resulting from the 
mutated allele forms the aggregates (23, 43, 44). However, a single experiment to 
transmit human 145 stop mutant prions to New Zealand White mice failed (19).  
Using H/D exchange coupled to NMR spectroscopy, we showed that the Q160X and 
N174X stop mutants of the human prion protein have a common solvent-protected 
core (Fig. 3) that starts at residue 109 and ends at residue 142. Residues 160QVYY163, 
which form beta-strand 2 in the native PrP structure, are not part of the fibrillar core 
of these stop mutants. In addition, residues 144 –156 that form helix1 in the native 
structure (8) remain highly solvent-accessible in amyloid fibrils of humPrP(23–159). 
In vitro aggregated amyloid fibrils of Q160X and Y145X are morphologically similar 
according to electron microscopy (20, 22) and have similar proteinase K cleavage 
sites (22). Moreover, solid-state NMR measurements of Y145X located the beta-
sheet-rich amyloid core to residues 112–140 (24). Taken together the data suggest that 
their amyloid fibrils share a common structure starting at residue 109–112 and ending 
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at residue 140–142. The identified fibril core is consistent with a major PrP fragment 
of 7 kDa that was detected in amyloid fibrils purified from the 145stop mutant (43), 
from the 227stop mutant (44), and from Gerstmann-Sträussler-Scheinker brains and 
spans residues 81– 82 to 144 –153 (45). Moreover, the fibrillar core represents the 
most conserved sequence element in mammalian and non mammalian prion proteins 
(46) and encompasses the peptide fragment 112–119 that is essential for the 
replication of the infectious agent in tissue culture (47).  
Recently, some of us determined the backbone fold of amyloid fibrils of the Y145X 
stop mutant by application of the CS-Rosetta structure calculation program to 
experimental solid- state NMR chemical shifts (24, 48). The calculations revealed a 
left-handed beta-helix formed by three beta-strands. The Met-129 side chain is located 
in the beginning of the third beta-strand and points inward to the hydrophobic core of 
the left-handed beta-helix. The structural model is well supported by the solvent 
accessibility of individual side chains obtained by mass spectrometry. Met-129 shows 
a pronounced reduction of solvent accessibility in the amyloid state (Fig. 4), in line 
with the structural model proposed for the Y145X stop mutant (48).  
Besides Met-129, the side chains of Tyr-128 and Leu-130 are solvent-protected in the 
amyloid state according to mass spectrometry (Fig. 4). In the beta-helix model of the 
Y145X stop mutant, the two residues belong, together with Met-129, to a single beta-
strand formed by 128YMLGSAMSR136 (48). The experimental solvent accessibilities 
of the 128YMLGSAMSR136 beta-strand suggest that both sides of this beta-strand are 
protected. The side harboring the Met-129 side chain forms the hydrophobic core of 
the beta-helix. In contrast, the side harboring Tyr-128 and Leu-130 is not protected in 
a single filament. A possible explanation for the solvent protection of the Tyr-128 and 
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Leu-130 side chains in light of the beta-helix model could be the pairing of two or 
more filaments, a hypothesis that would be supported by the dimensions of amyloid 
fibrils of the prion stop mutants observed by electron microscopy (22).  
 
FIGURE 4. Burial of the Met-129 side chain in amyloid fibrils of humPrP(108 –
143). A, tandem MS spectra of oxidized humPrP(108 –143). The oxidized amino acid 
and its corresponding fragment ions containing the modification are depicted in red, 
and b and y ions indicate fragmentation of the peptide bond conserving the charge to 
the N or C terminus, respectively. In the peptide MLGSAMSRPIIHF (129 –141), 
residues Met-129, Leu-130, and Met-134 are oxidized. B, time-course modifications 
of single residues for the fibrillar (dashed line) and monomeric state (solid line). 
Error bars correspond to S.E. obtained from independent measurements on two 
fibrillar and two monomeric samples.  
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In humans, the disease phenotype is modified by a methionine/valine polymorphism 
at codon 129 of the prion protein gene in addition to the prion type. Increasing 
evidence suggests that changes between methionine and valine do not affect the 
folding or stability of the native structure, implying that its influence takes place at 
downstream stages in the disease. Based on the broadening of the signals of Met-129 
in solid-state NMR measurements of the Y145X stop mutant, it was suggested that 
Met-129 is located in a flexible loop (24). In contrast, using a combination of H/D 
exchange coupled to NMR spectroscopy and hydroxyl radical probing detected by 
mass spectrometry, we demonstrate that the amide proton of Met-129 has slow 
solvent exchange in the fibrillar state and that its side chain becomes buried upon 
aggregation into amyloid. We therefore attribute the line broadening observed in 
solid-state NMR experiments for residues 121–141 (25) to dynamics between 
different filaments. At the same time, a high rigidity of a single PrP filament is 
supported by the finding that submicrosecond time scale dynamics are uniform across 
the amyloid core (25).  
In agreement with the burial of Met-129 in the amyloid core, the presence of a valine 
residue at position 129 strongly enhanced aggregation of humPrP(108–143) (Fig. 5A). 
The strong effect of the Val-129 substitution might at first sight appear surprising as 
the Val-129 variant of humPrP(23–144) converted to amyloid fibrils only slightly 
faster than Met-129 in previous in vitro studies (49). We attribute the differences to 
the entropic barrier provided by the unstructured residues 23–108 thereby masking 
differences between different PrP variants. In support of an entropic barrier, 
aggregation of humPrP(23–144) and humPrP(23–159) requires several fold higher 
concentrations than humPrP(108–143) (Fig. 5A) (22). Importantly, both the Met-129 
and the Val-129 humPrP(108–143) peptide displayed a shorter nucleation phase than 
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their 1:1 combination modeling the heterozygous situation. Indeed, humans that are 
heterozygote at codon 129 of the prion protein gene are relatively protected from 
prion diseases, and homozygotes, either methionine or valine, are 2– 4-fold more 
susceptible (50).  
 
FIGURE 5. Importance of residue 129 for aggregation of humPrP(108 –143). A, 
fibrillization kinetics of humPrP(108 –143) variants. Error bars correspond to S.D. (at 
least three data sets). B, electron micrograph of wild-type humPrP(108–143). The 
average diameter was 7–9 nm. C, electron micrograph of M109K humPrP(108–143). 
The black bar indicates 200 nm. D, seeding fibrillization of Met-129, M129D, and 
M129N humPrP(108–143) by amyloid seeds of Met-129 humPrP(108–143). The 
concentration of the seed was 5%. Data for Met-129 humPrP(108 –143) without seed 
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(gray) were taken from panel A.  
TABLE 1  
Quantification of aggregate formation of wild-type and M109K humPrP(108–
143) by centrifugation and protein quantification using UV absorbance.  
 
The finding that the Val-129 variant aggregates faster than Met-129 of humPrP(23–
144) is in contrast to previous aggregation experiments using recombinant PrP(90–
231), where methionine is more aggregation-promoting than valine (51).  
Besides differences in the experimental settings, an explanation may be that the C-
terminally truncated mutants aggregate to a different prion type than the N-terminally 
truncated one. From large epidemiological studies, we know that 87% of the 
methionine-homozygous sporadic Creutzfeldt-Jakob disease subjects accumulate 
prion type 1 and 97.5% of the valine homozygous Creutzfeldt-Jakob disease subjects 
accumulate prion type 2 (2). Taking this into account, the observed structure, starting 
at 109–112 and ending at 140–142, may represent the structural motif of prion type 2.  
In summary, we demonstrated that the polymorphic residue 129 is deeply 
buried in the amyloid core of stop mutants of the human prion protein. In line with its 
burial in the amyloid core structure, the identity of the 129 side chain is important for 
aggregation into amyloid fibrils. Our data support a critical role of the polymorphic 
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Figure S1. One-dimensional proton NMR spectrum of humPrP(108-143). The small 
dispersion in the amide proton (~8.2 ppm) and methyl region (0-1 ppm) demonstrates 




Figure S2. Tandem MS spectra of modified (oxidized) humPrP(108-143) peptides. 
The oxidized amino acid and its corresponding fragment ions containing the 
modification are depicted in red, b and y ions indicate fragmentation of the peptide 
bond conserving the charge to the N- or C- terminus, respectively; subindex 0 
indicates loss of water.(i.e b-H2O) a-f) Oxidized amino acids found in peptide 
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129MLGSAMSRPIIHF141: a) M129, L130, M134 b) M129, M134 and R136; c) 
M129, P137 and I139; d) M134, I138, I139; e) M134 and F141 and f) M129, M134 
and H140. g-h) Oxidized amino acids in the peptide 109-128: g) M112 and Y128 are 
oxidized, note the immonium ion of H (non modified); h) Modification in M109 and 
M112; of note immonium ions of H111 and Y128 are non-oxidized indicating that 
M112 is the actual oxidized residue. Spectra a-f) are from fibrillar samples, whereas 
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